new BindingDB logo
myBDB logout
Compile Data Set for Download or QSAR

Found 158 hits with Last Name = 'bosch' and Initial = 'j'   
Target/Host
(Institution)
LigandTarget/Host
Links
Ligand
Links
Trg + Lig
Links
Ki
nM
ΔG°
kJ/mole
IC50
nM
Kd
nM
EC50/IC50
nM
koff
s-1
kon
M-1s-1
pHTemp
°C
1-Deoxy-D-xylulose-5-phosphate synthase (DXP synthase))


(Escherichia coli K-12 (Enterobacteria))
BDBM108228
PNG
(1‐nitroso‐2‐naphthol (Substrate ...)
Show SMILES Oc1ccc2ccccc2c1N=O
Show InChI InChI=1S/C10H7NO2/c12-9-6-5-7-3-1-2-4-8(7)10(9)11-13/h1-6,12H
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
GoogleScholar
AffyNet 
Purchase

PC cid
PC sid
UniChem
Article
PubMed
4.22E+5 -20.0 1.07E+6n/an/an/an/a8.037



The Johns Hopkins University School of Medicine, 725 North Wolfe St, Baltimore, MD 21205, USA



Assay Description
Reaction mixtures containing HEPES (100mM, pH 8.0, 2mM MgCl2, 5mM NaCl), ThDP (1mM), BSA (1mg/mL), DMSO (10%, v/v), ᴅ-GAP (30µM), pyruvate...


Chembiochem 14: 1309-15 (2013)


Article DOI: 10.1002/cbic.201300187
BindingDB Entry DOI: 10.7270/Q2J101T3
More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM221898
PNG
(US9315463, 1)
Show SMILES CN(CCCCCCCCCNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12)C1CC[C@@H](CC1)OC(=O)C(O)(c1cccs1)c1cccs1 |r,wU:13.13,30.35,(5.28,4.23,;5.28,2.69,;3.94,1.93,;2.61,2.69,;1.27,1.93,;-.06,2.69,;-1.39,1.93,;-2.73,2.69,;-4.06,1.93,;-5.39,2.69,;-6.73,1.93,;-8.06,2.69,;-9.39,1.93,;-10.73,2.69,;-10.73,4.23,;-12.06,1.93,;-13.4,2.69,;-14.73,1.93,;-14.73,.38,;-16.06,-.38,;-13.4,-.38,;-13.4,-1.93,;-12.06,-2.69,;-12.06,-4.23,;-10.73,-1.93,;-10.73,-.38,;-12.06,.38,;6.61,1.93,;6.61,.38,;7.94,-.38,;9.28,.38,;9.28,1.93,;7.94,2.69,;10.61,-.38,;11.94,.38,;11.94,1.93,;13.28,-.38,;14.61,-1.15,;12.51,-1.72,;10.97,-1.72,;10.49,-3.18,;11.74,-4.09,;12.98,-3.18,;14.05,.95,;15.59,.95,;16.06,2.41,;14.82,3.32,;13.57,2.41,)|
Show InChI InChI=1/C37H49N3O6S2/c1-40(26-13-15-27(16-14-26)46-36(44)37(45,32-11-9-23-47-32)33-12-10-24-48-33)22-8-6-4-2-3-5-7-21-38-25-31(42)28-17-19-30(41)35-29(28)18-20-34(43)39-35/h9-12,17-20,23-24,26-27,31,38,41-42,45H,2-8,13-16,21-22,25H2,1H3,(H,39,43)/t26?,27-,31-/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 0.200n/an/an/an/an/an/a



Almirall, S.A.

US Patent


Assay Description
The study of binding to human muscarinic M1, M2, M3, M4 and M5 receptors was performed using commercial membranes (Perkin Elmer) prepared from CHO-K1...


US Patent US9315463 (2016)


BindingDB Entry DOI: 10.7270/Q24X56MM
More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM200747
PNG
(US9233108, 9 | US9757383, Example 9)
Show SMILES COc1cc(-c2noc(CCCN(C)[C@H]3CC[C@@H](CC3)OC(=O)C(O)(c3cccs3)c3cccs3)n2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12 |wU:17.20,wD:43.48,14.13,(3.51,-4.33,;4.85,-5.1,;6.18,-4.33,;6.18,-2.79,;7.51,-2.02,;7.51,-.48,;8.76,.43,;8.28,1.89,;6.74,1.89,;5.84,3.14,;6.46,4.54,;5.56,5.79,;6.18,7.2,;7.72,7.36,;5.28,8.44,;5.91,9.85,;5,11.09,;3.47,10.93,;2.84,9.53,;3.75,8.28,;2.56,12.18,;1.03,12.02,;.41,10.61,;.13,13.26,;1.37,14.17,;-.78,14.51,;-2.32,14.51,;-2.79,15.98,;-1.55,16.88,;-.3,15.98,;-1.12,12.36,;-1.12,10.82,;-2.58,10.34,;-3.49,11.59,;-2.58,12.84,;6.27,.43,;8.85,-2.79,;10.18,-2.02,;8.85,-4.33,;7.51,-5.1,;7.51,-6.64,;8.85,-7.41,;8.85,-8.95,;10.18,-9.72,;11.51,-8.95,;10.18,-11.26,;8.85,-12.03,;8.85,-13.57,;10.18,-14.34,;10.18,-15.88,;11.51,-13.57,;12.85,-14.34,;14.18,-13.57,;15.51,-14.34,;14.18,-12.03,;12.85,-11.26,;11.51,-12.03,)|
Show InChI InChI=1S/C41H44ClN5O8S2/c1-47(25-9-11-26(12-10-25)54-40(51)41(52,34-6-4-18-56-34)35-7-5-19-57-35)17-3-8-37-45-39(46-55-37)29-21-33(53-2)24(20-30(29)42)22-43-23-32(49)27-13-15-31(48)38-28(27)14-16-36(50)44-38/h4-7,13-16,18-21,25-26,32,43,48-49,52H,3,8-12,17,22-23H2,1-2H3,(H,44,50)/t25-,26-,32-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 0.200n/an/an/an/an/an/a



ALMIRALL, S.A.

US Patent


Assay Description
The study of binding to human muscarinic M1, M2, M3, M4 and M5 receptors was performed using commercial membranes (Perkin Elmer) prepared from CHO-K1...


US Patent US9233108 (2016)


BindingDB Entry DOI: 10.7270/Q23J3BSN
More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM200747
PNG
(US9233108, 9 | US9757383, Example 9)
Show SMILES COc1cc(-c2noc(CCCN(C)[C@H]3CC[C@@H](CC3)OC(=O)C(O)(c3cccs3)c3cccs3)n2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12 |wU:17.20,wD:43.48,14.13,(3.51,-4.33,;4.85,-5.1,;6.18,-4.33,;6.18,-2.79,;7.51,-2.02,;7.51,-.48,;8.76,.43,;8.28,1.89,;6.74,1.89,;5.84,3.14,;6.46,4.54,;5.56,5.79,;6.18,7.2,;7.72,7.36,;5.28,8.44,;5.91,9.85,;5,11.09,;3.47,10.93,;2.84,9.53,;3.75,8.28,;2.56,12.18,;1.03,12.02,;.41,10.61,;.13,13.26,;1.37,14.17,;-.78,14.51,;-2.32,14.51,;-2.79,15.98,;-1.55,16.88,;-.3,15.98,;-1.12,12.36,;-1.12,10.82,;-2.58,10.34,;-3.49,11.59,;-2.58,12.84,;6.27,.43,;8.85,-2.79,;10.18,-2.02,;8.85,-4.33,;7.51,-5.1,;7.51,-6.64,;8.85,-7.41,;8.85,-8.95,;10.18,-9.72,;11.51,-8.95,;10.18,-11.26,;8.85,-12.03,;8.85,-13.57,;10.18,-14.34,;10.18,-15.88,;11.51,-13.57,;12.85,-14.34,;14.18,-13.57,;15.51,-14.34,;14.18,-12.03,;12.85,-11.26,;11.51,-12.03,)|
Show InChI InChI=1S/C41H44ClN5O8S2/c1-47(25-9-11-26(12-10-25)54-40(51)41(52,34-6-4-18-56-34)35-7-5-19-57-35)17-3-8-37-45-39(46-55-37)29-21-33(53-2)24(20-30(29)42)22-43-23-32(49)27-13-15-31(48)38-28(27)14-16-36(50)44-38/h4-7,13-16,18-21,25-26,32,43,48-49,52H,3,8-12,17,22-23H2,1-2H3,(H,44,50)/t25-,26-,32-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 0.200n/an/an/an/an/an/a



Almirall, S.A.

US Patent




US Patent US9757383 (2017)

More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM200741
PNG
(US9233108, 1 | US9757383, Example 1)
Show SMILES CN(CCCn1c2ccc(CNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2oc1=O)[C@H]1CC[C@@H](CC1)OC(=O)C(O)(c1cccs1)c1cccs1 |wU:35.42,wD:13.13,32.35,(1.12,5.55,;2.62,5.23,;3.1,3.77,;2.07,2.62,;2.54,1.16,;1.51,.02,;1.83,-1.49,;3.17,-2.26,;3.17,-3.8,;1.83,-4.57,;1.83,-6.11,;3.17,-6.88,;3.17,-8.42,;4.5,-9.19,;5.84,-8.42,;4.5,-10.73,;3.17,-11.5,;3.17,-13.04,;4.5,-13.81,;4.5,-15.35,;5.84,-13.04,;7.17,-13.81,;8.5,-13.04,;9.84,-13.81,;8.5,-11.5,;7.17,-10.73,;5.84,-11.5,;.5,-3.8,;.5,-2.26,;-.64,-1.23,;-.02,.18,;-.79,1.51,;3.65,6.38,;5.16,6.06,;6.19,7.2,;5.71,8.67,;4.21,8.99,;3.18,7.84,;6.75,9.81,;6.27,11.28,;4.76,11.6,;7.3,12.42,;8.44,11.39,;8.33,13.56,;8.01,15.07,;9.34,15.84,;10.49,14.81,;9.86,13.4,;6.16,13.45,;4.65,13.13,;3.88,14.46,;4.91,15.61,;6.32,14.98,)|
Show InChI InChI=1S/C39H42N4O8S2/c1-42(25-8-10-26(11-9-25)50-37(47)39(49,33-5-2-19-52-33)34-6-3-20-53-34)17-4-18-43-29-14-7-24(21-32(29)51-38(43)48)22-40-23-31(45)27-12-15-30(44)36-28(27)13-16-35(46)41-36/h2-3,5-7,12-16,19-21,25-26,31,40,44-45,49H,4,8-11,17-18,22-23H2,1H3,(H,41,46)/t25-,26-,31-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 0.300n/an/an/an/an/an/a



ALMIRALL, S.A.

US Patent


Assay Description
The study of binding to human muscarinic M1, M2, M3, M4 and M5 receptors was performed using commercial membranes (Perkin Elmer) prepared from CHO-K1...


US Patent US9233108 (2016)


BindingDB Entry DOI: 10.7270/Q23J3BSN
More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM200741
PNG
(US9233108, 1 | US9757383, Example 1)
Show SMILES CN(CCCn1c2ccc(CNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2oc1=O)[C@H]1CC[C@@H](CC1)OC(=O)C(O)(c1cccs1)c1cccs1 |wU:35.42,wD:13.13,32.35,(1.12,5.55,;2.62,5.23,;3.1,3.77,;2.07,2.62,;2.54,1.16,;1.51,.02,;1.83,-1.49,;3.17,-2.26,;3.17,-3.8,;1.83,-4.57,;1.83,-6.11,;3.17,-6.88,;3.17,-8.42,;4.5,-9.19,;5.84,-8.42,;4.5,-10.73,;3.17,-11.5,;3.17,-13.04,;4.5,-13.81,;4.5,-15.35,;5.84,-13.04,;7.17,-13.81,;8.5,-13.04,;9.84,-13.81,;8.5,-11.5,;7.17,-10.73,;5.84,-11.5,;.5,-3.8,;.5,-2.26,;-.64,-1.23,;-.02,.18,;-.79,1.51,;3.65,6.38,;5.16,6.06,;6.19,7.2,;5.71,8.67,;4.21,8.99,;3.18,7.84,;6.75,9.81,;6.27,11.28,;4.76,11.6,;7.3,12.42,;8.44,11.39,;8.33,13.56,;8.01,15.07,;9.34,15.84,;10.49,14.81,;9.86,13.4,;6.16,13.45,;4.65,13.13,;3.88,14.46,;4.91,15.61,;6.32,14.98,)|
Show InChI InChI=1S/C39H42N4O8S2/c1-42(25-8-10-26(11-9-25)50-37(47)39(49,33-5-2-19-52-33)34-6-3-20-53-34)17-4-18-43-29-14-7-24(21-32(29)51-38(43)48)22-40-23-31(45)27-12-15-30(44)36-28(27)13-16-35(46)41-36/h2-3,5-7,12-16,19-21,25-26,31,40,44-45,49H,4,8-11,17-18,22-23H2,1H3,(H,41,46)/t25-,26-,31-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 0.300n/an/an/an/an/an/a



Almirall, S.A.

US Patent




US Patent US9757383 (2017)

More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM221909
PNG
(US9315463, 25)
Show SMILES COc1cc(OCCCCN(C)[C@H]2CC[C@@H](CC2)OC(=O)C(O)(c2cccs2)c2cccs2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12 |r,wU:40.44,15.18,wD:12.11,(-5.39,-3.84,;-4.06,-3.07,;-4.06,-1.53,;-2.73,-.76,;-2.73,.78,;-1.39,1.55,;-.06,.78,;1.27,1.55,;2.61,.78,;3.94,1.55,;5.28,.78,;5.28,-.76,;6.61,1.55,;7.94,.78,;9.28,1.55,;9.28,3.09,;7.94,3.86,;6.61,3.09,;10.61,3.86,;11.94,3.09,;11.94,1.55,;13.28,3.86,;14.61,4.63,;14.05,2.53,;13.57,1.06,;14.82,.16,;16.06,1.06,;15.59,2.53,;12.51,5.2,;13.41,6.44,;12.51,7.69,;11.04,7.21,;11.04,5.67,;-4.06,1.55,;-4.06,3.09,;-5.39,.78,;-5.39,-.76,;-6.73,-1.53,;-8.06,-.76,;-9.39,-1.53,;-10.73,-.76,;-10.73,.78,;-12.06,-1.53,;-13.4,-.76,;-14.73,-1.53,;-14.73,-3.07,;-16.06,-3.84,;-13.4,-3.84,;-13.4,-5.38,;-12.06,-6.15,;-12.06,-7.69,;-10.73,-5.38,;-10.73,-3.84,;-12.06,-3.07,)|
Show InChI InChI=1/C40H46ClN3O8S2/c1-44(26-9-11-27(12-10-26)52-39(48)40(49,35-7-5-19-53-35)36-8-6-20-54-36)17-3-4-18-51-34-22-33(50-2)25(21-30(34)41)23-42-24-32(46)28-13-15-31(45)38-29(28)14-16-37(47)43-38/h5-8,13-16,19-22,26-27,32,42,45-46,49H,3-4,9-12,17-18,23-24H2,1-2H3,(H,43,47)/t26-,27-,32-/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 0.300n/an/an/an/an/an/a



Almirall, S.A.

US Patent


Assay Description
The study of binding to human muscarinic M1, M2, M3, M4 and M5 receptors was performed using commercial membranes (Perkin Elmer) prepared from CHO-K1...


US Patent US9315463 (2016)


BindingDB Entry DOI: 10.7270/Q24X56MM
More data for this
Ligand-Target Pair
Beta-2 adrenergic receptor and beta-3 adrenergic receptor


(Homo sapiens (Human))
BDBM221910
PNG
(US9315463, 26)
Show SMILES COc1cc(NC(=O)OCCN(C)[C@H]2CC[C@@H](CC2)OC(=O)C(O)(c2cccs2)c2cccs2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2NC(=O)COc12 |r,wU:41.45,16.19,wD:13.12,(-2.73,-3.84,;-4.06,-3.07,;-4.06,-1.53,;-2.73,-.76,;-2.73,.78,;-1.39,1.55,;-.06,.78,;-.06,-.76,;1.27,1.55,;2.61,.78,;3.94,1.55,;5.28,.78,;5.28,-.76,;6.61,1.55,;7.94,.78,;9.28,1.55,;9.28,3.09,;7.94,3.86,;6.61,3.09,;10.61,3.86,;11.94,3.09,;11.94,1.55,;13.28,3.86,;14.61,4.63,;14.05,2.53,;13.57,1.06,;14.82,.16,;16.06,1.06,;15.59,2.53,;12.51,5.2,;13.41,6.44,;12.51,7.69,;11.04,7.21,;11.04,5.67,;-4.06,1.55,;-4.06,3.09,;-5.39,.78,;-5.39,-.76,;-6.73,-1.53,;-8.06,-.76,;-9.39,-1.53,;-10.73,-.76,;-10.73,.78,;-12.06,-1.53,;-13.4,-.76,;-14.73,-1.53,;-14.73,-3.07,;-16.06,-3.84,;-13.4,-3.84,;-13.4,-5.38,;-12.06,-6.15,;-12.06,-7.69,;-10.73,-5.38,;-10.73,-3.84,;-12.06,-3.07,)|
Show InChI InChI=1/C38H43ClN4O10S2/c1-43(23-7-9-24(10-8-23)53-36(47)38(49,31-5-3-15-54-31)32-6-4-16-55-32)13-14-51-37(48)41-27-18-30(50-2)22(17-26(27)39)19-40-20-29(45)25-11-12-28(44)34-35(25)52-21-33(46)42-34/h3-6,11-12,15-18,23-24,29,40,44-45,49H,7-10,13-14,19-21H2,1-2H3,(H,41,48)(H,42,46)/t23-,24-,29-/s2
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 0.380n/an/an/an/an/a25



Almirall, S.A.

US Patent


Assay Description
The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are ov...


US Patent US9315463 (2016)


BindingDB Entry DOI: 10.7270/Q24X56MM
More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM200753
PNG
(US9233108, 18 | US9757383, Example 18)
Show SMILES CN(CCCn1nnc2cc(CNC[C@H](O)c3ccc(O)c4NC(=O)COc34)ccc12)[C@H]1CC[C@@H](CC1)OC(=O)[C@@](O)(C1CCCC1)c1cccs1 |wU:40.45,34.41,wD:40.44,14.14,31.34,(6.31,-4.67,;7.82,-4.35,;8.3,-2.88,;7.26,-1.74,;7.74,-.27,;6.71,.87,;5.18,.71,;4.55,2.12,;5.7,3.15,;5.7,4.69,;7.03,5.46,;7.03,7,;5.7,7.77,;5.7,9.31,;4.36,10.08,;3.03,9.31,;4.36,11.62,;5.7,12.39,;5.7,13.93,;4.36,14.7,;4.36,16.24,;3.03,13.93,;1.7,14.7,;.36,13.93,;-.97,14.7,;.36,12.39,;1.7,11.62,;3.03,12.39,;8.36,4.69,;8.36,3.15,;7.03,2.38,;8.85,-5.49,;8.37,-6.95,;9.4,-8.1,;10.91,-7.78,;11.39,-6.31,;10.36,-5.17,;11.94,-8.92,;13.45,-8.6,;13.92,-7.14,;14.48,-9.75,;15.62,-8.72,;13.33,-10.78,;13.49,-12.31,;12.09,-12.94,;11.06,-11.79,;11.83,-10.46,;15.51,-10.89,;17.04,-10.73,;17.67,-12.14,;16.52,-13.17,;15.19,-12.4,)|
Show InChI InChI=1S/C38H48N6O7S/c1-43(26-10-12-27(13-11-26)51-37(48)38(49,25-6-2-3-7-25)33-8-4-19-52-33)17-5-18-44-30-15-9-24(20-29(30)41-42-44)21-39-22-32(46)28-14-16-31(45)35-36(28)50-23-34(47)40-35/h4,8-9,14-16,19-20,25-27,32,39,45-46,49H,2-3,5-7,10-13,17-18,21-23H2,1H3,(H,40,47)/t26-,27-,32-,38+/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 0.400n/an/an/an/an/an/a



Almirall, S.A.

US Patent




US Patent US9757383 (2017)

More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM200748
PNG
(US9233108, 10 | US9757383, Example 10)
Show SMILES COc1cc(OCC(=O)N(C)CCN(C)[C@H]2CC[C@@H](CC2)OC(=O)C(O)(c2cccs2)c2cccs2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12 |wU:18.21,wD:43.47,15.14,(14.69,-1.46,;16.03,-.69,;16.03,.85,;14.69,1.62,;14.69,3.16,;13.36,3.93,;12.03,3.16,;10.69,3.93,;10.69,5.47,;9.36,3.16,;9.36,1.62,;8.02,3.93,;6.69,3.16,;5.36,3.93,;5.36,5.47,;4.02,3.16,;2.69,3.93,;1.36,3.16,;1.36,1.62,;2.69,.85,;4.02,1.62,;.02,.85,;.02,-.69,;1.36,-1.46,;-1.31,-1.46,;-2.08,-.13,;-2.65,-2.23,;-2.81,-3.76,;-4.31,-4.08,;-5.08,-2.75,;-4.05,-1.6,;-.54,-2.79,;.99,-2.96,;1.31,-4.46,;-.02,-5.23,;-1.17,-4.2,;16.03,3.93,;16.03,5.47,;17.36,3.16,;17.36,1.62,;18.69,.85,;20.03,1.62,;21.36,.85,;22.69,1.62,;22.69,3.16,;24.03,.85,;24.03,-.69,;25.36,-1.46,;26.7,-.69,;28.03,-1.46,;26.7,.85,;28.03,1.62,;28.03,3.16,;29.36,3.93,;26.7,3.93,;25.36,3.16,;25.36,1.62,)|
Show InChI InChI=1S/C41H47ClN4O9S2/c1-45(26-8-10-27(11-9-26)55-40(51)41(52,35-6-4-18-56-35)36-7-5-19-57-36)16-17-46(2)38(50)24-54-34-21-33(53-3)25(20-30(34)42)22-43-23-32(48)28-12-14-31(47)39-29(28)13-15-37(49)44-39/h4-7,12-15,18-21,26-27,32,43,47-48,52H,8-11,16-17,22-24H2,1-3H3,(H,44,49)/t26-,27-,32-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 0.400n/an/an/an/an/an/a



Almirall, S.A.

US Patent




US Patent US9757383 (2017)

More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM200744
PNG
(US9233108, 5 | US9757383, Example 5)
Show SMILES CN(CCCc1nc(no1)-c1ccc(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1)[C@H]1CC[C@@H](CC1)OC(=O)C(O)(c1cccs1)c1cccs1 |wU:36.43,wD:17.18,33.36,(6.52,7.15,;4.99,6.98,;4.37,5.58,;5.27,4.33,;4.65,2.92,;5.55,1.68,;5.07,.21,;6.32,-.69,;7.57,.21,;7.09,1.68,;6.32,-2.23,;7.65,-3,;7.65,-4.54,;6.32,-5.31,;6.32,-6.85,;7.65,-7.62,;7.65,-9.16,;8.99,-9.93,;10.32,-9.16,;8.99,-11.47,;7.65,-12.24,;7.65,-13.78,;8.99,-14.55,;8.99,-16.09,;10.32,-13.78,;11.66,-14.55,;12.99,-13.78,;14.32,-14.55,;12.99,-12.24,;11.66,-11.47,;10.32,-12.24,;4.99,-4.54,;4.99,-3,;4.09,8.23,;4.71,9.64,;3.81,10.88,;2.28,10.72,;1.65,9.31,;2.56,8.07,;1.37,11.97,;-.16,11.81,;-.79,10.4,;-1.06,13.05,;.18,13.96,;-1.97,14.3,;-3.51,14.3,;-3.99,15.76,;-2.74,16.67,;-1.49,15.76,;-2.31,12.15,;-2.31,10.61,;-3.77,10.13,;-4.68,11.38,;-3.77,12.62,)|
Show InChI InChI=1S/C40H43N5O7S2/c1-45(27-12-14-28(15-13-27)51-39(49)40(50,33-5-3-21-53-33)34-6-4-22-54-34)20-2-7-36-43-38(44-52-36)26-10-8-25(9-11-26)23-41-24-32(47)29-16-18-31(46)37-30(29)17-19-35(48)42-37/h3-6,8-11,16-19,21-22,27-28,32,41,46-47,50H,2,7,12-15,20,23-24H2,1H3,(H,42,48)/t27-,28-,32-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 0.400n/an/an/an/an/an/a



Almirall, S.A.

US Patent




US Patent US9757383 (2017)

More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM200742
PNG
(US9233108, 2 | US9757383, Example 2)
Show SMILES CN(CCCn1c2ccc(CNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2[nH]c1=O)[C@H]1CC[C@@H](CC1)OC(=O)C(O)(c1cccs1)c1cccs1 |wU:35.42,wD:13.13,32.35,(6.74,6.38,;5.23,6.06,;4.76,4.59,;5.79,3.45,;5.31,1.99,;6.34,.84,;6.02,-.67,;4.69,-1.44,;4.69,-2.98,;6.02,-3.75,;6.02,-5.29,;7.36,-6.06,;7.36,-7.6,;8.69,-8.37,;10.02,-7.6,;8.69,-9.91,;7.36,-10.68,;7.36,-12.22,;8.69,-12.99,;8.69,-14.53,;10.02,-12.22,;11.36,-12.99,;12.69,-12.22,;14.03,-12.99,;12.69,-10.68,;11.36,-9.91,;10.02,-10.68,;7.36,-2.98,;7.36,-1.44,;8.5,-.4,;7.88,1,;8.65,2.34,;4.2,7.2,;4.68,8.67,;3.65,9.81,;2.14,9.49,;1.67,8.03,;2.7,6.88,;1.11,10.64,;-.39,10.32,;-.87,8.85,;-1.42,11.46,;-.28,12.49,;-2.45,12.61,;-3.99,12.44,;-4.61,13.85,;-3.47,14.88,;-2.13,14.11,;-2.57,10.43,;-2.41,8.9,;-3.81,8.27,;-4.84,9.42,;-4.07,10.75,)|
Show InChI InChI=1S/C39H43N5O7S2/c1-43(25-8-10-26(11-9-25)51-37(48)39(50,33-5-2-19-52-33)34-6-3-20-53-34)17-4-18-44-30-14-7-24(21-29(30)41-38(44)49)22-40-23-32(46)27-12-15-31(45)36-28(27)13-16-35(47)42-36/h2-3,5-7,12-16,19-21,25-26,32,40,45-46,50H,4,8-11,17-18,22-23H2,1H3,(H,41,49)(H,42,47)/t25-,26-,32-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 0.400n/an/an/an/an/an/a



Almirall, S.A.

US Patent




US Patent US9757383 (2017)

More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM200753
PNG
(US9233108, 18 | US9757383, Example 18)
Show SMILES CN(CCCn1nnc2cc(CNC[C@H](O)c3ccc(O)c4NC(=O)COc34)ccc12)[C@H]1CC[C@@H](CC1)OC(=O)[C@@](O)(C1CCCC1)c1cccs1 |wU:40.45,34.41,wD:40.44,14.14,31.34,(6.31,-4.67,;7.82,-4.35,;8.3,-2.88,;7.26,-1.74,;7.74,-.27,;6.71,.87,;5.18,.71,;4.55,2.12,;5.7,3.15,;5.7,4.69,;7.03,5.46,;7.03,7,;5.7,7.77,;5.7,9.31,;4.36,10.08,;3.03,9.31,;4.36,11.62,;5.7,12.39,;5.7,13.93,;4.36,14.7,;4.36,16.24,;3.03,13.93,;1.7,14.7,;.36,13.93,;-.97,14.7,;.36,12.39,;1.7,11.62,;3.03,12.39,;8.36,4.69,;8.36,3.15,;7.03,2.38,;8.85,-5.49,;8.37,-6.95,;9.4,-8.1,;10.91,-7.78,;11.39,-6.31,;10.36,-5.17,;11.94,-8.92,;13.45,-8.6,;13.92,-7.14,;14.48,-9.75,;15.62,-8.72,;13.33,-10.78,;13.49,-12.31,;12.09,-12.94,;11.06,-11.79,;11.83,-10.46,;15.51,-10.89,;17.04,-10.73,;17.67,-12.14,;16.52,-13.17,;15.19,-12.4,)|
Show InChI InChI=1S/C38H48N6O7S/c1-43(26-10-12-27(13-11-26)51-37(48)38(49,25-6-2-3-7-25)33-8-4-19-52-33)17-5-18-44-30-15-9-24(20-29(30)41-42-44)21-39-22-32(46)28-14-16-31(45)35-36(28)50-23-34(47)40-35/h4,8-9,14-16,19-20,25-27,32,39,45-46,49H,2-3,5-7,10-13,17-18,21-23H2,1H3,(H,40,47)/t26-,27-,32-,38+/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 0.400n/an/an/an/an/an/a



ALMIRALL, S.A.

US Patent


Assay Description
The study of binding to human muscarinic M1, M2, M3, M4 and M5 receptors was performed using commercial membranes (Perkin Elmer) prepared from CHO-K1...


US Patent US9233108 (2016)


BindingDB Entry DOI: 10.7270/Q23J3BSN
More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM200748
PNG
(US9233108, 10 | US9757383, Example 10)
Show SMILES COc1cc(OCC(=O)N(C)CCN(C)[C@H]2CC[C@@H](CC2)OC(=O)C(O)(c2cccs2)c2cccs2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12 |wU:18.21,wD:43.47,15.14,(14.69,-1.46,;16.03,-.69,;16.03,.85,;14.69,1.62,;14.69,3.16,;13.36,3.93,;12.03,3.16,;10.69,3.93,;10.69,5.47,;9.36,3.16,;9.36,1.62,;8.02,3.93,;6.69,3.16,;5.36,3.93,;5.36,5.47,;4.02,3.16,;2.69,3.93,;1.36,3.16,;1.36,1.62,;2.69,.85,;4.02,1.62,;.02,.85,;.02,-.69,;1.36,-1.46,;-1.31,-1.46,;-2.08,-.13,;-2.65,-2.23,;-2.81,-3.76,;-4.31,-4.08,;-5.08,-2.75,;-4.05,-1.6,;-.54,-2.79,;.99,-2.96,;1.31,-4.46,;-.02,-5.23,;-1.17,-4.2,;16.03,3.93,;16.03,5.47,;17.36,3.16,;17.36,1.62,;18.69,.85,;20.03,1.62,;21.36,.85,;22.69,1.62,;22.69,3.16,;24.03,.85,;24.03,-.69,;25.36,-1.46,;26.7,-.69,;28.03,-1.46,;26.7,.85,;28.03,1.62,;28.03,3.16,;29.36,3.93,;26.7,3.93,;25.36,3.16,;25.36,1.62,)|
Show InChI InChI=1S/C41H47ClN4O9S2/c1-45(26-8-10-27(11-9-26)55-40(51)41(52,35-6-4-18-56-35)36-7-5-19-57-36)16-17-46(2)38(50)24-54-34-21-33(53-3)25(20-30(34)42)22-43-23-32(48)28-12-14-31(47)39-29(28)13-15-37(49)44-39/h4-7,12-15,18-21,26-27,32,43,47-48,52H,8-11,16-17,22-24H2,1-3H3,(H,44,49)/t26-,27-,32-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 0.400n/an/an/an/an/an/a



ALMIRALL, S.A.

US Patent


Assay Description
The study of binding to human muscarinic M1, M2, M3, M4 and M5 receptors was performed using commercial membranes (Perkin Elmer) prepared from CHO-K1...


US Patent US9233108 (2016)


BindingDB Entry DOI: 10.7270/Q23J3BSN
More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM200744
PNG
(US9233108, 5 | US9757383, Example 5)
Show SMILES CN(CCCc1nc(no1)-c1ccc(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1)[C@H]1CC[C@@H](CC1)OC(=O)C(O)(c1cccs1)c1cccs1 |wU:36.43,wD:17.18,33.36,(6.52,7.15,;4.99,6.98,;4.37,5.58,;5.27,4.33,;4.65,2.92,;5.55,1.68,;5.07,.21,;6.32,-.69,;7.57,.21,;7.09,1.68,;6.32,-2.23,;7.65,-3,;7.65,-4.54,;6.32,-5.31,;6.32,-6.85,;7.65,-7.62,;7.65,-9.16,;8.99,-9.93,;10.32,-9.16,;8.99,-11.47,;7.65,-12.24,;7.65,-13.78,;8.99,-14.55,;8.99,-16.09,;10.32,-13.78,;11.66,-14.55,;12.99,-13.78,;14.32,-14.55,;12.99,-12.24,;11.66,-11.47,;10.32,-12.24,;4.99,-4.54,;4.99,-3,;4.09,8.23,;4.71,9.64,;3.81,10.88,;2.28,10.72,;1.65,9.31,;2.56,8.07,;1.37,11.97,;-.16,11.81,;-.79,10.4,;-1.06,13.05,;.18,13.96,;-1.97,14.3,;-3.51,14.3,;-3.99,15.76,;-2.74,16.67,;-1.49,15.76,;-2.31,12.15,;-2.31,10.61,;-3.77,10.13,;-4.68,11.38,;-3.77,12.62,)|
Show InChI InChI=1S/C40H43N5O7S2/c1-45(27-12-14-28(15-13-27)51-39(49)40(50,33-5-3-21-53-33)34-6-4-22-54-34)20-2-7-36-43-38(44-52-36)26-10-8-25(9-11-26)23-41-24-32(47)29-16-18-31(46)37-30(29)17-19-35(48)42-37/h3-6,8-11,16-19,21-22,27-28,32,41,46-47,50H,2,7,12-15,20,23-24H2,1H3,(H,42,48)/t27-,28-,32-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 0.400n/an/an/an/an/an/a



ALMIRALL, S.A.

US Patent


Assay Description
The study of binding to human muscarinic M1, M2, M3, M4 and M5 receptors was performed using commercial membranes (Perkin Elmer) prepared from CHO-K1...


US Patent US9233108 (2016)


BindingDB Entry DOI: 10.7270/Q23J3BSN
More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM200742
PNG
(US9233108, 2 | US9757383, Example 2)
Show SMILES CN(CCCn1c2ccc(CNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2[nH]c1=O)[C@H]1CC[C@@H](CC1)OC(=O)C(O)(c1cccs1)c1cccs1 |wU:35.42,wD:13.13,32.35,(6.74,6.38,;5.23,6.06,;4.76,4.59,;5.79,3.45,;5.31,1.99,;6.34,.84,;6.02,-.67,;4.69,-1.44,;4.69,-2.98,;6.02,-3.75,;6.02,-5.29,;7.36,-6.06,;7.36,-7.6,;8.69,-8.37,;10.02,-7.6,;8.69,-9.91,;7.36,-10.68,;7.36,-12.22,;8.69,-12.99,;8.69,-14.53,;10.02,-12.22,;11.36,-12.99,;12.69,-12.22,;14.03,-12.99,;12.69,-10.68,;11.36,-9.91,;10.02,-10.68,;7.36,-2.98,;7.36,-1.44,;8.5,-.4,;7.88,1,;8.65,2.34,;4.2,7.2,;4.68,8.67,;3.65,9.81,;2.14,9.49,;1.67,8.03,;2.7,6.88,;1.11,10.64,;-.39,10.32,;-.87,8.85,;-1.42,11.46,;-.28,12.49,;-2.45,12.61,;-3.99,12.44,;-4.61,13.85,;-3.47,14.88,;-2.13,14.11,;-2.57,10.43,;-2.41,8.9,;-3.81,8.27,;-4.84,9.42,;-4.07,10.75,)|
Show InChI InChI=1S/C39H43N5O7S2/c1-43(25-8-10-26(11-9-25)51-37(48)39(50,33-5-2-19-52-33)34-6-3-20-53-34)17-4-18-44-30-14-7-24(21-29(30)41-38(44)49)22-40-23-32(46)27-12-15-31(45)36-28(27)13-16-35(47)42-36/h2-3,5-7,12-16,19-21,25-26,32,40,45-46,50H,4,8-11,17-18,22-23H2,1H3,(H,41,49)(H,42,47)/t25-,26-,32-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 0.400n/an/an/an/an/an/a



ALMIRALL, S.A.

US Patent


Assay Description
The study of binding to human muscarinic M1, M2, M3, M4 and M5 receptors was performed using commercial membranes (Perkin Elmer) prepared from CHO-K1...


US Patent US9233108 (2016)


BindingDB Entry DOI: 10.7270/Q23J3BSN
More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM200749
PNG
(US9233108, 11 | US9757383, Example 11)
Show SMILES CN(CCCn1c2ccc(CNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2sc1=O)[C@H]1CC[C@@H](CC1)OC(=O)C(O)(c1cccs1)c1cccs1 |wU:35.42,wD:13.13,32.35,(1.12,5.55,;2.62,5.23,;3.1,3.77,;2.07,2.62,;2.54,1.16,;1.51,.02,;1.83,-1.49,;3.17,-2.26,;3.17,-3.8,;1.83,-4.57,;1.83,-6.11,;3.17,-6.88,;3.17,-8.42,;4.5,-9.19,;5.84,-8.42,;4.5,-10.73,;3.17,-11.5,;3.17,-13.04,;4.5,-13.81,;4.5,-15.35,;5.84,-13.04,;7.17,-13.81,;8.5,-13.04,;9.84,-13.81,;8.5,-11.5,;7.17,-10.73,;5.84,-11.5,;.5,-3.8,;.5,-2.26,;-.64,-1.23,;-.02,.18,;-.79,1.51,;3.65,6.38,;5.16,6.06,;6.19,7.2,;5.71,8.67,;4.21,8.99,;3.18,7.84,;6.75,9.81,;6.27,11.28,;4.76,11.6,;7.3,12.42,;8.44,11.39,;8.33,13.56,;8.01,15.07,;9.34,15.84,;10.49,14.81,;9.86,13.4,;6.16,13.45,;4.65,13.13,;3.88,14.46,;4.91,15.61,;6.32,14.98,)|
Show InChI InChI=1S/C39H42N4O7S3/c1-42(25-8-10-26(11-9-25)50-37(47)39(49,33-5-2-19-51-33)34-6-3-20-52-34)17-4-18-43-29-14-7-24(21-32(29)53-38(43)48)22-40-23-31(45)27-12-15-30(44)36-28(27)13-16-35(46)41-36/h2-3,5-7,12-16,19-21,25-26,31,40,44-45,49H,4,8-11,17-18,22-23H2,1H3,(H,41,46)/t25-,26-,31-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 0.5n/an/an/an/an/an/a



Almirall, S.A.

US Patent




US Patent US9757383 (2017)

More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM200749
PNG
(US9233108, 11 | US9757383, Example 11)
Show SMILES CN(CCCn1c2ccc(CNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2sc1=O)[C@H]1CC[C@@H](CC1)OC(=O)C(O)(c1cccs1)c1cccs1 |wU:35.42,wD:13.13,32.35,(1.12,5.55,;2.62,5.23,;3.1,3.77,;2.07,2.62,;2.54,1.16,;1.51,.02,;1.83,-1.49,;3.17,-2.26,;3.17,-3.8,;1.83,-4.57,;1.83,-6.11,;3.17,-6.88,;3.17,-8.42,;4.5,-9.19,;5.84,-8.42,;4.5,-10.73,;3.17,-11.5,;3.17,-13.04,;4.5,-13.81,;4.5,-15.35,;5.84,-13.04,;7.17,-13.81,;8.5,-13.04,;9.84,-13.81,;8.5,-11.5,;7.17,-10.73,;5.84,-11.5,;.5,-3.8,;.5,-2.26,;-.64,-1.23,;-.02,.18,;-.79,1.51,;3.65,6.38,;5.16,6.06,;6.19,7.2,;5.71,8.67,;4.21,8.99,;3.18,7.84,;6.75,9.81,;6.27,11.28,;4.76,11.6,;7.3,12.42,;8.44,11.39,;8.33,13.56,;8.01,15.07,;9.34,15.84,;10.49,14.81,;9.86,13.4,;6.16,13.45,;4.65,13.13,;3.88,14.46,;4.91,15.61,;6.32,14.98,)|
Show InChI InChI=1S/C39H42N4O7S3/c1-42(25-8-10-26(11-9-25)50-37(47)39(49,33-5-2-19-51-33)34-6-3-20-52-34)17-4-18-43-29-14-7-24(21-32(29)53-38(43)48)22-40-23-31(45)27-12-15-30(44)36-28(27)13-16-35(46)41-36/h2-3,5-7,12-16,19-21,25-26,31,40,44-45,49H,4,8-11,17-18,22-23H2,1H3,(H,41,46)/t25-,26-,31-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 0.5n/an/an/an/an/an/a



ALMIRALL, S.A.

US Patent


Assay Description
The study of binding to human muscarinic M1, M2, M3, M4 and M5 receptors was performed using commercial membranes (Perkin Elmer) prepared from CHO-K1...


US Patent US9233108 (2016)


BindingDB Entry DOI: 10.7270/Q23J3BSN
More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM200752
PNG
(US9233108, 17 | US9757383, Example 16)
Show SMILES CN(CCCn1nnc2cc(CNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)ccc12)[C@H]1CC[C@@H](CC1)OC(=O)[C@@](O)(C1CCCC1)c1cccs1 |wU:40.45,34.41,wD:40.44,14.14,31.34,(9.03,5.39,;7.52,5.07,;7.04,3.6,;8.07,2.46,;7.6,.99,;8.63,-.15,;10.16,.01,;10.79,-1.4,;9.64,-2.43,;9.64,-3.97,;8.31,-4.74,;8.31,-6.28,;9.64,-7.05,;9.64,-8.59,;10.98,-9.36,;12.31,-8.59,;10.98,-10.9,;9.64,-11.67,;9.64,-13.21,;10.98,-13.98,;10.98,-15.52,;12.31,-13.21,;13.64,-13.98,;14.98,-13.21,;16.31,-13.98,;14.98,-11.67,;13.64,-10.9,;12.31,-11.67,;6.97,-3.97,;6.97,-2.43,;8.31,-1.66,;6.49,6.21,;6.97,7.68,;5.93,8.82,;4.43,8.5,;3.95,7.04,;4.98,5.89,;3.4,9.65,;1.89,9.32,;1.42,7.86,;.86,10.47,;-.28,9.44,;2.01,11.5,;1.84,13.03,;3.25,13.66,;4.28,12.51,;3.51,11.18,;-.17,11.61,;-1.7,11.45,;-2.33,12.86,;-1.18,13.89,;.15,13.12,)|
Show InChI InChI=1S/C39H48N6O6S/c1-44(27-10-12-28(13-11-27)51-38(49)39(50,26-6-2-3-7-26)35-8-4-21-52-35)19-5-20-45-32-16-9-25(22-31(32)42-43-45)23-40-24-34(47)29-14-17-33(46)37-30(29)15-18-36(48)41-37/h4,8-9,14-18,21-22,26-28,34,40,46-47,50H,2-3,5-7,10-13,19-20,23-24H2,1H3,(H,41,48)/t27-,28-,34-,39+/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 0.600n/an/an/an/an/an/a



ALMIRALL, S.A.

US Patent


Assay Description
The study of binding to human muscarinic M1, M2, M3, M4 and M5 receptors was performed using commercial membranes (Perkin Elmer) prepared from CHO-K1...


US Patent US9233108 (2016)


BindingDB Entry DOI: 10.7270/Q23J3BSN
More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM339881
PNG
(US9757383, Example 4 | trans-4-[{3-[5-({[(2R)-2-hy...)
Show SMILES CN(CCCn1ccc2cc(CNC[C@H](O)c3ccc(O)c4NCC=Cc34)ccc12)[C@H]1CC[C@@H](CC1)OC(=O)C(O)(c1cccs1)c1cccs1 |wU:30.33,14.14,wD:33.40,c:24,(4.07,14.5,;2.56,14.18,;2.09,12.71,;3.12,11.57,;4.62,11.89,;5.65,10.75,;7.19,10.91,;7.81,9.5,;6.67,8.47,;6.67,6.93,;5.33,6.16,;5.33,4.62,;4,3.85,;4,2.31,;2.67,1.54,;1.33,2.31,;2.67,,;1.33,-.77,;1.33,-2.31,;2.67,-3.08,;2.67,-4.62,;4,-2.31,;5.33,-3.08,;6.67,-2.31,;6.67,-.77,;5.33,,;4,-.77,;4,6.93,;4,8.47,;5.33,9.24,;1.53,15.32,;.03,15,;-1,16.15,;-.53,17.61,;.98,17.93,;2.01,16.79,;-1.56,18.76,;-3.06,18.44,;-3.54,16.97,;-4.1,19.58,;-5.24,18.55,;-5.13,20.73,;-4.81,22.23,;-6.14,23,;-7.28,21.97,;-6.66,20.57,;-2.95,20.61,;-1.44,20.29,;-.67,21.63,;-1.7,22.77,;-3.11,22.14,)|
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 0.600n/an/an/an/an/an/a



Almirall, S.A.

US Patent




US Patent US9757383 (2017)

More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM339892
PNG
(US9757383, Example 17 | trans-4-[{3-[5-({[(2R)-2-h...)
Show SMILES CN(CCCn1nnc2cc(CNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)ccc12)[C@H]1CC[C@@H](CC1)c1ccsc1[C@](O)(C1CCCC1)C([O-])=O |wU:34.41,42.47,wD:14.14,31.34,42.48,(-.72,16.28,;.79,15.96,;1.26,14.5,;.23,13.36,;.71,11.89,;-.32,10.75,;-1.85,10.91,;-2.48,9.5,;-1.33,8.47,;-1.33,6.93,;,6.16,;,4.62,;1.33,3.85,;1.33,2.31,;2.67,1.54,;4,2.31,;2.67,,;1.33,-.77,;1.33,-2.31,;2.67,-3.08,;2.67,-4.62,;4,-2.31,;5.33,-3.08,;6.67,-2.31,;8,-3.08,;6.67,-.77,;5.33,,;4,-.77,;1.33,6.93,;1.33,8.47,;,9.24,;1.82,17.11,;3.33,16.79,;4.36,17.93,;3.88,19.4,;2.37,19.72,;1.34,18.57,;4.91,20.54,;6.44,20.38,;7.07,21.79,;5.92,22.82,;4.59,22.05,;3.18,22.67,;2.56,21.27,;3.81,24.08,;3.04,25.42,;4.07,26.56,;5.48,25.93,;5.32,24.4,;1.78,23.3,;1.62,24.83,;.53,22.4,)|
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 0.600n/an/an/an/an/an/a



Almirall, S.A.

US Patent




US Patent US9757383 (2017)

More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM200743
PNG
(US9233108, 4)
Show SMILES CN(CCCn1ccc2cc(CNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)ccc12)[C@H]1CC[C@@H](CC1)OC(=O)C(O)(c1cccs1)c1cccs1 |wU:34.41,wD:14.14,31.34,(6.72,6.42,;5.21,6.1,;4.73,4.64,;5.76,3.5,;5.29,2.03,;6.32,.89,;7.85,1.05,;8.48,-.36,;7.33,-1.39,;7.33,-2.93,;6,-3.7,;6,-5.24,;7.33,-6.01,;7.33,-7.55,;8.67,-8.32,;10,-7.55,;8.67,-9.86,;7.33,-10.63,;7.33,-12.17,;8.67,-12.94,;8.67,-14.48,;10,-12.17,;11.33,-12.94,;12.67,-12.17,;14,-12.94,;12.67,-10.63,;11.33,-9.86,;10,-10.63,;4.67,-2.93,;4.67,-1.39,;6,-.62,;4.18,7.25,;4.66,8.71,;3.62,9.86,;2.12,9.54,;1.64,8.07,;2.67,6.93,;1.09,10.68,;-.42,10.36,;-.89,8.9,;-1.45,11.51,;-.3,12.54,;-2.48,12.65,;-4.01,12.49,;-4.64,13.9,;-3.49,14.93,;-2.16,14.16,;-2.59,10.48,;-2.43,8.94,;-3.84,8.32,;-4.87,9.46,;-4.1,10.8,)|
Show InChI InChI=1S/C40H44N4O6S2/c1-43(28-8-10-29(11-9-28)50-39(48)40(49,35-5-2-21-51-35)36-6-3-22-52-36)18-4-19-44-20-17-27-23-26(7-14-32(27)44)24-41-25-34(46)30-12-15-33(45)38-31(30)13-16-37(47)42-38/h2-3,5-7,12-17,20-23,28-29,34,41,45-46,49H,4,8-11,18-19,24-25H2,1H3,(H,42,47)/t28-,29-,34-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 0.600n/an/an/an/an/an/a



ALMIRALL, S.A.

US Patent


Assay Description
The study of binding to human muscarinic M1, M2, M3, M4 and M5 receptors was performed using commercial membranes (Perkin Elmer) prepared from CHO-K1...


US Patent US9233108 (2016)


BindingDB Entry DOI: 10.7270/Q23J3BSN
More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM221907
PNG
(US9315463, 20)
Show SMILES COc1cc(NC(=O)CCN(C)[C@H]2CC[C@@H](CC2)OC(=O)C(O)(c2cccs2)c2cccs2)c(Cl)cc1CCNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12 |r,wU:41.45,15.18,wD:12.11,(-4.06,3.86,;-2.73,3.09,;-2.73,1.55,;-1.39,.78,;-1.39,-.76,;-.06,-1.53,;1.27,-.76,;1.27,.78,;2.61,-1.53,;3.94,-.76,;5.28,-1.53,;5.28,-3.07,;6.61,-.76,;7.94,-1.53,;9.28,-.76,;9.28,.78,;7.94,1.55,;6.61,.78,;10.61,1.55,;11.94,.78,;11.94,-.76,;13.28,1.55,;14.61,2.32,;14.05,.22,;13.57,-1.25,;14.82,-2.15,;16.06,-1.25,;15.59,.22,;12.51,2.89,;13.41,4.13,;12.51,5.38,;11.04,4.9,;11.04,3.36,;-2.73,-1.53,;-2.73,-3.07,;-4.06,-.76,;-4.06,.78,;-5.39,1.55,;-6.73,.78,;-8.06,1.55,;-9.39,.78,;-10.73,1.55,;-10.73,3.09,;-12.06,.78,;-13.4,1.55,;-14.73,.78,;-14.73,-.76,;-16.06,-1.53,;-13.4,-1.53,;-13.4,-3.07,;-12.06,-3.84,;-12.06,-5.38,;-10.73,-3.07,;-10.73,-1.53,;-12.06,-.76,)|
Show InChI InChI=1/C40H45ClN4O8S2/c1-45(25-7-9-26(10-8-25)53-39(50)40(51,34-5-3-19-54-34)35-6-4-20-55-35)18-16-37(49)43-30-22-33(52-2)24(21-29(30)41)15-17-42-23-32(47)27-11-13-31(46)38-28(27)12-14-36(48)44-38/h3-6,11-14,19-22,25-26,32,42,46-47,51H,7-10,15-18,23H2,1-2H3,(H,43,49)(H,44,48)/t25-,26-,32-/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 0.700n/an/an/an/an/an/a



Almirall, S.A.

US Patent


Assay Description
The study of binding to human muscarinic M1, M2, M3, M4 and M5 receptors was performed using commercial membranes (Perkin Elmer) prepared from CHO-K1...


US Patent US9315463 (2016)


BindingDB Entry DOI: 10.7270/Q24X56MM
More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM200754
PNG
(US9233108, 19 | US9757383, Example 19)
Show SMILES CN(CCCn1c2ccc(CCNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2oc1=O)[C@H]1CC[C@@H](CC1)OC(=O)C(O)(c1cccs1)c1cccs1 |wU:36.43,wD:14.14,33.36,(5.47,2.57,;6.5,3.72,;8,3.4,;8.48,1.93,;9.98,1.61,;10.46,.15,;11.93,-.33,;13.26,.44,;14.59,-.33,;14.59,-1.87,;15.93,-2.64,;15.93,-4.18,;17.26,-4.95,;17.26,-6.49,;18.59,-7.26,;19.93,-6.49,;18.59,-8.8,;17.26,-9.57,;17.26,-11.11,;18.59,-11.88,;18.59,-13.42,;19.93,-11.11,;21.26,-11.88,;22.59,-11.11,;23.93,-11.88,;22.59,-9.57,;21.26,-8.8,;19.93,-9.57,;13.26,-2.64,;11.93,-1.87,;10.46,-2.34,;9.56,-1.1,;8.02,-1.1,;6.02,5.18,;7.05,6.33,;6.57,7.79,;5.07,8.11,;4.04,6.97,;4.51,5.5,;4.59,9.58,;3.09,9.9,;2.06,8.75,;2.61,11.36,;4.07,11.84,;2.13,12.83,;.67,13.3,;.67,14.84,;2.13,15.32,;3.04,14.07,;1.15,10.89,;.67,9.42,;-.87,9.42,;-1.35,10.89,;-.1,11.79,)|
Show InChI InChI=1S/C40H44N4O8S2/c1-43(26-8-10-27(11-9-26)51-38(48)40(50,34-5-2-21-53-34)35-6-3-22-54-35)19-4-20-44-30-14-7-25(23-33(30)52-39(44)49)17-18-41-24-32(46)28-12-15-31(45)37-29(28)13-16-36(47)42-37/h2-3,5-7,12-16,21-23,26-27,32,41,45-46,50H,4,8-11,17-20,24H2,1H3,(H,42,47)/t26-,27-,32-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 0.800n/an/an/an/an/an/a



ALMIRALL, S.A.

US Patent


Assay Description
The study of binding to human muscarinic M1, M2, M3, M4 and M5 receptors was performed using commercial membranes (Perkin Elmer) prepared from CHO-K1...


US Patent US9233108 (2016)


BindingDB Entry DOI: 10.7270/Q23J3BSN
More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM200754
PNG
(US9233108, 19 | US9757383, Example 19)
Show SMILES CN(CCCn1c2ccc(CCNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2oc1=O)[C@H]1CC[C@@H](CC1)OC(=O)C(O)(c1cccs1)c1cccs1 |wU:36.43,wD:14.14,33.36,(5.47,2.57,;6.5,3.72,;8,3.4,;8.48,1.93,;9.98,1.61,;10.46,.15,;11.93,-.33,;13.26,.44,;14.59,-.33,;14.59,-1.87,;15.93,-2.64,;15.93,-4.18,;17.26,-4.95,;17.26,-6.49,;18.59,-7.26,;19.93,-6.49,;18.59,-8.8,;17.26,-9.57,;17.26,-11.11,;18.59,-11.88,;18.59,-13.42,;19.93,-11.11,;21.26,-11.88,;22.59,-11.11,;23.93,-11.88,;22.59,-9.57,;21.26,-8.8,;19.93,-9.57,;13.26,-2.64,;11.93,-1.87,;10.46,-2.34,;9.56,-1.1,;8.02,-1.1,;6.02,5.18,;7.05,6.33,;6.57,7.79,;5.07,8.11,;4.04,6.97,;4.51,5.5,;4.59,9.58,;3.09,9.9,;2.06,8.75,;2.61,11.36,;4.07,11.84,;2.13,12.83,;.67,13.3,;.67,14.84,;2.13,15.32,;3.04,14.07,;1.15,10.89,;.67,9.42,;-.87,9.42,;-1.35,10.89,;-.1,11.79,)|
Show InChI InChI=1S/C40H44N4O8S2/c1-43(26-8-10-27(11-9-26)51-38(48)40(50,34-5-2-21-53-34)35-6-3-22-54-35)19-4-20-44-30-14-7-25(23-33(30)52-39(44)49)17-18-41-24-32(46)28-12-15-31(45)37-29(28)13-16-36(47)42-37/h2-3,5-7,12-16,21-23,26-27,32,41,45-46,50H,4,8-11,17-20,24H2,1H3,(H,42,47)/t26-,27-,32-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 0.800n/an/an/an/an/an/a



Almirall, S.A.

US Patent




US Patent US9757383 (2017)

More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM200750
PNG
(US9233108, 15 | US9757383, Example 15)
Show SMILES CN(CCCn1c2ccc(CNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2oc1=O)[C@H]1CC[C@@H](CC1)OC(=O)C1(C)c2ccccc2Oc2ccccc12 |wU:35.42,wD:13.13,32.35,(3.58,2.63,;5.09,2.31,;5.57,.85,;4.54,-.3,;5.01,-1.76,;3.98,-2.91,;4.3,-4.41,;5.64,-5.18,;5.64,-6.72,;4.3,-7.49,;4.3,-9.03,;5.64,-9.8,;5.64,-11.34,;6.97,-12.11,;8.3,-11.34,;6.97,-13.65,;5.64,-14.42,;5.64,-15.96,;6.97,-16.73,;6.97,-18.27,;8.3,-15.96,;9.64,-16.73,;10.97,-15.96,;12.3,-16.73,;10.97,-14.42,;9.64,-13.65,;8.3,-14.42,;2.97,-6.72,;2.97,-5.18,;1.82,-4.15,;2.45,-2.75,;1.68,-1.41,;6.12,3.45,;7.63,3.13,;8.66,4.28,;8.18,5.74,;6.68,6.06,;5.65,4.92,;9.21,6.89,;8.74,8.35,;7.23,8.67,;9.77,9.5,;8.24,9.71,;10.03,11.01,;8.85,12,;9.12,13.52,;10.57,14.05,;11.75,13.06,;11.48,11.54,;12.66,10.55,;12.39,9.03,;13.57,8.04,;13.31,6.53,;11.86,6,;10.68,6.99,;10.95,8.51,)|
Show InChI InChI=1S/C44H46N4O8/c1-44(32-8-3-5-10-37(32)55-38-11-6-4-9-33(38)44)42(52)54-29-15-13-28(14-16-29)47(2)22-7-23-48-34-19-12-27(24-39(34)56-43(48)53)25-45-26-36(50)30-17-20-35(49)41-31(30)18-21-40(51)46-41/h3-6,8-12,17-21,24,28-29,36,45,49-50H,7,13-16,22-23,25-26H2,1-2H3,(H,46,51)/t28-,29-,36-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 1n/an/an/an/an/an/a



ALMIRALL, S.A.

US Patent


Assay Description
The study of binding to human muscarinic M1, M2, M3, M4 and M5 receptors was performed using commercial membranes (Perkin Elmer) prepared from CHO-K1...


US Patent US9233108 (2016)


BindingDB Entry DOI: 10.7270/Q23J3BSN
More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM200750
PNG
(US9233108, 15 | US9757383, Example 15)
Show SMILES CN(CCCn1c2ccc(CNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2oc1=O)[C@H]1CC[C@@H](CC1)OC(=O)C1(C)c2ccccc2Oc2ccccc12 |wU:35.42,wD:13.13,32.35,(3.58,2.63,;5.09,2.31,;5.57,.85,;4.54,-.3,;5.01,-1.76,;3.98,-2.91,;4.3,-4.41,;5.64,-5.18,;5.64,-6.72,;4.3,-7.49,;4.3,-9.03,;5.64,-9.8,;5.64,-11.34,;6.97,-12.11,;8.3,-11.34,;6.97,-13.65,;5.64,-14.42,;5.64,-15.96,;6.97,-16.73,;6.97,-18.27,;8.3,-15.96,;9.64,-16.73,;10.97,-15.96,;12.3,-16.73,;10.97,-14.42,;9.64,-13.65,;8.3,-14.42,;2.97,-6.72,;2.97,-5.18,;1.82,-4.15,;2.45,-2.75,;1.68,-1.41,;6.12,3.45,;7.63,3.13,;8.66,4.28,;8.18,5.74,;6.68,6.06,;5.65,4.92,;9.21,6.89,;8.74,8.35,;7.23,8.67,;9.77,9.5,;8.24,9.71,;10.03,11.01,;8.85,12,;9.12,13.52,;10.57,14.05,;11.75,13.06,;11.48,11.54,;12.66,10.55,;12.39,9.03,;13.57,8.04,;13.31,6.53,;11.86,6,;10.68,6.99,;10.95,8.51,)|
Show InChI InChI=1S/C44H46N4O8/c1-44(32-8-3-5-10-37(32)55-38-11-6-4-9-33(38)44)42(52)54-29-15-13-28(14-16-29)47(2)22-7-23-48-34-19-12-27(24-39(34)56-43(48)53)25-45-26-36(50)30-17-20-35(49)41-31(30)18-21-40(51)46-41/h3-6,8-12,17-21,24,28-29,36,45,49-50H,7,13-16,22-23,25-26H2,1-2H3,(H,46,51)/t28-,29-,36-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 1n/an/an/an/an/an/a



Almirall, S.A.

US Patent




US Patent US9757383 (2017)

More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM221904
PNG
(US9315463, 15)
Show SMILES COc1cc(NC(=O)CCCN[C@H]2CC[C@@H](CC2)OC(=O)C(O)(c2cccs2)c2cccs2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12 |r,wU:40.44,15.18,wD:12.11,(-5.39,-3.84,;-4.06,-3.07,;-4.06,-1.53,;-2.73,-.76,;-2.73,.78,;-1.39,1.55,;-.06,.78,;-.06,-.76,;1.27,1.55,;2.61,.78,;3.94,1.55,;5.28,.78,;6.61,1.55,;7.94,.78,;9.28,1.55,;9.28,3.09,;7.94,3.86,;6.61,3.09,;10.61,3.86,;11.94,3.09,;11.94,1.55,;13.28,3.86,;14.61,4.63,;14.05,2.53,;13.57,1.06,;14.82,.16,;16.06,1.06,;15.59,2.53,;12.51,5.2,;13.41,6.44,;12.51,7.69,;11.04,7.21,;11.04,5.67,;-4.06,1.55,;-4.06,3.09,;-5.39,.78,;-5.39,-.76,;-6.73,-1.53,;-8.06,-.76,;-9.39,-1.53,;-10.73,-.76,;-10.73,.78,;-12.06,-1.53,;-13.4,-.76,;-14.73,-1.53,;-14.73,-3.07,;-16.06,-3.84,;-13.4,-3.84,;-13.4,-5.38,;-12.06,-6.15,;-12.06,-7.69,;-10.73,-5.38,;-10.73,-3.84,;-12.06,-3.07,)|
Show InChI InChI=1/C39H43ClN4O8S2/c1-51-32-20-29(28(40)19-23(32)21-41-22-31(46)26-12-14-30(45)37-27(26)13-15-36(48)44-37)43-35(47)7-2-16-42-24-8-10-25(11-9-24)52-38(49)39(50,33-5-3-17-53-33)34-6-4-18-54-34/h3-6,12-15,17-20,24-25,31,41-42,45-46,50H,2,7-11,16,21-22H2,1H3,(H,43,47)(H,44,48)/t24-,25-,31-/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 1n/an/an/an/an/an/a



Almirall, S.A.

US Patent


Assay Description
The study of binding to human muscarinic M1, M2, M3, M4 and M5 receptors was performed using commercial membranes (Perkin Elmer) prepared from CHO-K1...


US Patent US9315463 (2016)


BindingDB Entry DOI: 10.7270/Q24X56MM
More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM221900
PNG
(US9315463, 9)
Show SMILES COc1cc(NC(=O)CCN(C)[C@H]2CC[C@@H](CC2)OC(=O)C(O)(c2cccs2)c2cccs2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12 |r,wU:40.44,15.18,wD:12.11,(-7.85,3.08,;-6.52,3.85,;-5.19,3.08,;-3.85,3.85,;-2.52,3.08,;-1.18,3.85,;.15,3.08,;.15,1.54,;1.48,3.85,;2.82,3.08,;4.15,3.85,;4.15,5.39,;5.48,3.08,;5.48,1.54,;6.82,.77,;8.15,1.54,;8.15,3.08,;6.82,3.85,;9.48,.77,;10.82,1.54,;10.82,3.08,;12.15,.77,;13.49,,;12.15,-.77,;10.91,-1.68,;11.38,-3.14,;12.92,-3.14,;13.4,-1.68,;13.49,1.54,;14.95,1.06,;15.86,2.31,;14.95,3.56,;13.49,3.08,;-2.52,1.54,;-1.18,.77,;-3.85,.77,;-5.19,1.54,;-6.52,.77,;-7.85,1.54,;-9.19,.77,;-10.52,1.54,;-10.52,3.08,;-11.85,.77,;-13.19,1.54,;-14.52,.77,;-14.52,-.77,;-15.86,-1.54,;-13.19,-1.54,;-13.19,-3.08,;-11.85,-3.85,;-11.85,-5.39,;-10.52,-3.08,;-10.52,-1.54,;-11.85,-.77,)|
Show InChI InChI=1/C39H43ClN4O8S2/c1-44(24-7-9-25(10-8-24)52-38(49)39(50,33-5-3-17-53-33)34-6-4-18-54-34)16-15-36(48)42-29-20-32(51-2)23(19-28(29)40)21-41-22-31(46)26-11-13-30(45)37-27(26)12-14-35(47)43-37/h3-6,11-14,17-20,24-25,31,41,45-46,50H,7-10,15-16,21-22H2,1-2H3,(H,42,48)(H,43,47)/t24-,25-,31-/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 1.10n/an/an/an/an/an/a



Almirall, S.A.

US Patent


Assay Description
The study of binding to human muscarinic M1, M2, M3, M4 and M5 receptors was performed using commercial membranes (Perkin Elmer) prepared from CHO-K1...


US Patent US9315463 (2016)


BindingDB Entry DOI: 10.7270/Q24X56MM
More data for this
Ligand-Target Pair
Beta-2 adrenergic receptor and beta-3 adrenergic receptor


(Homo sapiens (Human))
BDBM221912
PNG
(US9315463, 29)
Show SMILES COc1cc(NC(=O)OCCN(C)[C@H]2CC[C@@H](CC2)OC(=O)[C@@](O)(C2CCCC2)c2cccs2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12 |r,wU:41.45,16.19,22.30,wD:13.12,22.23,(-5.85,-3.78,;-4.52,-3.01,;-4.52,-1.47,;-3.19,-.7,;-3.19,.84,;-1.85,1.61,;-.52,.84,;-.52,-.7,;.82,1.61,;2.15,.84,;3.48,1.61,;4.82,.84,;4.82,-.7,;6.15,1.61,;7.48,.84,;8.82,1.61,;8.82,3.15,;7.48,3.92,;6.15,3.15,;10.15,3.92,;11.49,3.15,;11.49,1.61,;12.82,3.92,;14.15,4.69,;12.05,5.26,;12.52,6.72,;11.28,7.63,;10.03,6.72,;10.51,5.26,;14.15,3.15,;14.15,1.61,;15.62,1.14,;16.52,2.38,;15.62,3.63,;-4.52,1.61,;-4.52,3.15,;-5.85,.84,;-5.85,-.7,;-7.19,-1.47,;-8.52,-.7,;-9.85,-1.47,;-11.19,-.7,;-11.19,.84,;-12.52,-1.47,;-13.85,-.7,;-15.19,-1.47,;-15.19,-3.01,;-16.52,-3.78,;-13.85,-3.78,;-13.85,-5.32,;-12.52,-6.09,;-12.52,-7.63,;-11.19,-5.32,;-11.19,-3.78,;-12.52,-3.01,)|
Show InChI InChI=1/C40H49ClN4O9S/c1-45(26-9-11-27(12-10-26)54-38(49)40(51,25-6-3-4-7-25)35-8-5-19-55-35)17-18-53-39(50)43-31-21-34(52-2)24(20-30(31)41)22-42-23-33(47)28-13-15-32(46)37-29(28)14-16-36(48)44-37/h5,8,13-16,19-21,25-27,33,42,46-47,51H,3-4,6-7,9-12,17-18,22-23H2,1-2H3,(H,43,50)(H,44,48)/t26-,27-,33-,40+/s2
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 1.10n/an/an/an/an/a25



Almirall, S.A.

US Patent


Assay Description
The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are ov...


US Patent US9315463 (2016)


BindingDB Entry DOI: 10.7270/Q24X56MM
More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM221899
PNG
(US9315463, 2)
Show SMILES CN(CCOc1ccc(CCNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1)C1CC[C@@H](CC1)OC(=O)C(O)(c1cccs1)c1cccs1 |r,wU:13.13,32.38,(4.61,3.07,;4.61,1.53,;3.27,.76,;1.94,1.53,;.61,.76,;-.73,1.53,;-2.06,.76,;-3.39,1.53,;-3.39,3.07,;-4.73,3.84,;-6.06,3.07,;-7.39,3.84,;-8.73,3.07,;-10.06,3.84,;-10.06,5.38,;-11.4,3.07,;-12.73,3.84,;-14.06,3.07,;-14.06,1.53,;-15.4,.76,;-12.73,.76,;-12.73,-.78,;-11.4,-1.55,;-11.4,-3.09,;-10.06,-.78,;-10.06,.76,;-11.4,1.53,;-2.06,3.84,;-.73,3.07,;5.94,.76,;5.94,-.78,;7.28,-1.55,;8.61,-.78,;8.61,.76,;7.28,1.53,;9.94,-1.55,;11.28,-.78,;11.28,.76,;12.61,-1.55,;13.94,-2.32,;13.38,-.22,;14.92,-.22,;15.4,1.25,;14.15,2.15,;12.9,1.25,;11.84,-2.89,;10.38,-3.36,;10.38,-4.9,;11.84,-5.38,;12.75,-4.13,)|
Show InChI InChI=1/C38H43N3O7S2/c1-41(26-8-12-28(13-9-26)48-37(45)38(46,33-4-2-22-49-33)34-5-3-23-50-34)20-21-47-27-10-6-25(7-11-27)18-19-39-24-32(43)29-14-16-31(42)36-30(29)15-17-35(44)40-36/h2-7,10-11,14-17,22-23,26,28,32,39,42-43,46H,8-9,12-13,18-21,24H2,1H3,(H,40,44)/t26?,28-,32-/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 1.30n/an/an/an/an/an/a



Almirall, S.A.

US Patent


Assay Description
The study of binding to human muscarinic M1, M2, M3, M4 and M5 receptors was performed using commercial membranes (Perkin Elmer) prepared from CHO-K1...


US Patent US9315463 (2016)


BindingDB Entry DOI: 10.7270/Q24X56MM
More data for this
Ligand-Target Pair
Beta-2 adrenergic receptor and beta-3 adrenergic receptor


(Homo sapiens (Human))
BDBM221911
PNG
(US9315463, 28)
Show SMILES COc1cc(NC(=O)OCCN(C)[C@H]2CC[C@@H](CC2)OC(=O)[C@@](O)(C2CCCC2)c2ccccc2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12 |r,wU:42.46,16.19,22.22,wD:13.12,22.23,(-6.31,-3.88,;-4.98,-3.11,;-4.98,-1.57,;-3.64,-.8,;-3.64,.74,;-2.31,1.51,;-.98,.74,;-.98,-.8,;.36,1.51,;1.69,.74,;3.02,1.51,;4.36,.74,;4.36,-.8,;5.69,1.51,;7.03,.74,;8.36,1.51,;8.36,3.05,;7.03,3.82,;5.69,3.05,;9.69,3.82,;11.03,3.05,;11.03,1.51,;12.36,3.82,;13.13,2.49,;12.36,5.36,;13.61,6.27,;13.13,7.73,;11.59,7.73,;11.11,6.27,;13.9,3.82,;14.67,2.49,;16.21,2.49,;16.98,3.82,;16.21,5.15,;14.67,5.15,;-4.98,1.51,;-4.98,3.05,;-6.31,.74,;-6.31,-.8,;-7.64,-1.57,;-8.98,-.8,;-10.31,-1.57,;-11.65,-.8,;-11.65,.74,;-12.98,-1.57,;-14.31,-.8,;-15.65,-1.57,;-15.65,-3.11,;-16.98,-3.88,;-14.31,-3.88,;-14.31,-5.42,;-12.98,-6.19,;-12.98,-7.73,;-11.65,-5.42,;-11.65,-3.88,;-12.98,-3.11,)|
Show InChI InChI=1/C42H51ClN4O9/c1-47(29-12-14-30(15-13-29)56-40(51)42(53,28-10-6-7-11-28)27-8-4-3-5-9-27)20-21-55-41(52)45-34-23-37(54-2)26(22-33(34)43)24-44-25-36(49)31-16-18-35(48)39-32(31)17-19-38(50)46-39/h3-5,8-9,16-19,22-23,28-30,36,44,48-49,53H,6-7,10-15,20-21,24-25H2,1-2H3,(H,45,52)(H,46,50)/t29-,30-,36-,42-/s2
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 1.30n/an/an/an/an/a25



Almirall, S.A.

US Patent


Assay Description
The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are ov...


US Patent US9315463 (2016)


BindingDB Entry DOI: 10.7270/Q24X56MM
More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM339883
PNG
(US9757383, Example 6 | trans-4-[{2-[{[4-({[(2R)-2-...)
Show SMILES CN(CCN(C)C(=O)COc1ccc(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1)[C@H]1CC[C@@H](CC1)OC(=O)C(O)(c1cccs1)c1cccs1 |wU:33.35,17.17,wD:36.42,(-11.8,-7.7,;-13.34,-7.7,;-14.11,-9.03,;-13.34,-10.37,;-11.8,-10.37,;-11.03,-11.7,;-11.03,-9.03,;-10.87,-7.5,;-9.49,-9.03,;-8.72,-7.7,;-7.18,-7.7,;-6.41,-6.37,;-4.87,-6.37,;-4.1,-7.7,;-2.56,-7.7,;-1.79,-9.03,;-.25,-9.03,;.52,-10.37,;-.25,-11.7,;2.06,-10.37,;2.83,-11.7,;4.37,-11.7,;5.14,-10.37,;6.68,-10.37,;4.37,-9.03,;5.14,-7.7,;4.37,-6.37,;5.14,-5.03,;2.83,-6.37,;2.06,-7.7,;2.83,-9.03,;-4.87,-9.03,;-6.41,-9.03,;-14.11,-6.37,;-15.65,-6.37,;-16.42,-5.03,;-15.65,-3.7,;-14.11,-3.7,;-13.34,-5.03,;-16.42,-2.37,;-17.96,-2.37,;-18.73,-3.7,;-18.73,-1.03,;-20.06,-1.8,;-19.5,.3,;-18.87,1.71,;-20.01,2.74,;-21.35,1.97,;-21.03,.46,;-17.39,-.26,;-15.99,-.89,;-14.96,.26,;-15.73,1.59,;-17.23,1.27,)|
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 1.40n/an/an/an/an/an/a



Almirall, S.A.

US Patent




US Patent US9757383 (2017)

More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM221908
PNG
(US9315463, 22)
Show SMILES COc1cc(NC(=O)OCCN(C)[C@H]2CC[C@@H](CC2)OC(=O)C(O)(c2cccs2)c2cccs2)c(cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12)C#N |r,wU:40.44,16.19,wD:13.12,(-5.39,-3.84,;-4.06,-3.07,;-4.06,-1.53,;-2.73,-.76,;-2.73,.78,;-1.39,1.55,;-.06,.78,;-.06,-.76,;1.27,1.55,;2.61,.78,;3.94,1.55,;5.28,.78,;5.28,-.76,;6.61,1.55,;7.94,.78,;9.28,1.55,;9.28,3.09,;7.94,3.86,;6.61,3.09,;10.61,3.86,;11.94,3.09,;11.94,1.55,;13.28,3.86,;14.61,4.63,;14.05,2.53,;13.57,1.06,;14.82,.16,;16.06,1.06,;15.59,2.53,;12.51,5.2,;13.41,6.44,;12.51,7.69,;11.04,7.21,;11.04,5.67,;-4.06,1.55,;-5.39,.78,;-5.39,-.76,;-6.73,-1.53,;-8.06,-.76,;-9.39,-1.53,;-10.73,-.76,;-10.73,.78,;-12.06,-1.53,;-13.4,-.76,;-14.73,-1.53,;-14.73,-3.07,;-16.06,-3.84,;-13.4,-3.84,;-13.4,-5.38,;-12.06,-6.15,;-12.06,-7.69,;-10.73,-5.38,;-10.73,-3.84,;-12.06,-3.07,;-4.06,3.09,;-4.06,4.63,)|
Show InChI InChI=1/C40H43N5O9S2/c1-45(26-7-9-27(10-8-26)54-38(49)40(51,34-5-3-17-55-34)35-6-4-18-56-35)15-16-53-39(50)43-30-20-33(52-2)25(19-24(30)21-41)22-42-23-32(47)28-11-13-31(46)37-29(28)12-14-36(48)44-37/h3-6,11-14,17-20,26-27,32,42,46-47,51H,7-10,15-16,22-23H2,1-2H3,(H,43,50)(H,44,48)/t26-,27-,32-/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 1.40n/an/an/an/an/an/a



Almirall, S.A.

US Patent


Assay Description
The study of binding to human muscarinic M1, M2, M3, M4 and M5 receptors was performed using commercial membranes (Perkin Elmer) prepared from CHO-K1...


US Patent US9315463 (2016)


BindingDB Entry DOI: 10.7270/Q24X56MM
More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM200745
PNG
(US9233108, 6)
Show SMILES CN(CCN(C)C(=O)COc1ccc(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1)[C@H]1CC[C@@H](CC1)OC(C([O-])=O)(c1cccs1)c1cccs1 |wU:36.42,wD:17.17,33.35,(.89,-8.55,;.39,-10.01,;-1.12,-10.3,;-2.13,-9.14,;-3.64,-9.43,;-4.15,-10.88,;-4.65,-8.26,;-4.15,-6.81,;-6.16,-8.55,;-6.67,-10.01,;-8.18,-10.3,;-9.19,-9.14,;-10.7,-9.43,;-11.21,-10.88,;-12.72,-11.17,;-13.22,-12.63,;-14.73,-12.92,;-15.24,-14.38,;-14.23,-15.54,;-16.75,-14.67,;-17.76,-13.5,;-19.27,-13.79,;-19.77,-15.25,;-21.29,-15.54,;-18.77,-16.41,;-19.27,-17.87,;-18.26,-19.03,;-18.77,-20.49,;-16.75,-18.74,;-16.25,-17.29,;-17.25,-16.12,;-10.2,-12.05,;-8.68,-11.76,;1.4,-11.17,;.89,-12.63,;1.9,-13.79,;3.41,-13.5,;3.92,-12.05,;2.91,-10.88,;4.42,-14.67,;5.93,-14.38,;5.64,-12.86,;4.76,-11.6,;6.81,-11.86,;6.22,-15.89,;7.62,-16.54,;7.43,-18.07,;5.92,-18.36,;5.17,-17.01,;7.45,-14.08,;8.1,-12.69,;9.63,-12.88,;9.92,-14.39,;8.57,-15.14,)|
Show InChI InChI=1S/C40H46N4O8S2/c1-43(27-9-13-29(14-10-27)52-40(39(49)50,34-5-3-21-53-34)35-6-4-22-54-35)19-20-44(2)37(48)25-51-28-11-7-26(8-12-28)23-41-24-33(46)30-15-17-32(45)38-31(30)16-18-36(47)42-38/h3-8,11-12,15-18,21-22,27,29,33,41,45-46H,9-10,13-14,19-20,23-25H2,1-2H3,(H,42,47)(H,49,50)/p-1/t27-,29-,33-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 1.40n/an/an/an/an/an/a



ALMIRALL, S.A.

US Patent


Assay Description
The study of binding to human muscarinic M1, M2, M3, M4 and M5 receptors was performed using commercial membranes (Perkin Elmer) prepared from CHO-K1...


US Patent US9233108 (2016)


BindingDB Entry DOI: 10.7270/Q23J3BSN
More data for this
Ligand-Target Pair
Beta-2 adrenergic receptor and beta-3 adrenergic receptor


(Homo sapiens (Human))
BDBM200753
PNG
(US9233108, 18 | US9757383, Example 18)
Show SMILES CN(CCCn1nnc2cc(CNC[C@H](O)c3ccc(O)c4NC(=O)COc34)ccc12)[C@H]1CC[C@@H](CC1)OC(=O)[C@@](O)(C1CCCC1)c1cccs1 |wU:40.45,34.41,wD:40.44,14.14,31.34,(6.31,-4.67,;7.82,-4.35,;8.3,-2.88,;7.26,-1.74,;7.74,-.27,;6.71,.87,;5.18,.71,;4.55,2.12,;5.7,3.15,;5.7,4.69,;7.03,5.46,;7.03,7,;5.7,7.77,;5.7,9.31,;4.36,10.08,;3.03,9.31,;4.36,11.62,;5.7,12.39,;5.7,13.93,;4.36,14.7,;4.36,16.24,;3.03,13.93,;1.7,14.7,;.36,13.93,;-.97,14.7,;.36,12.39,;1.7,11.62,;3.03,12.39,;8.36,4.69,;8.36,3.15,;7.03,2.38,;8.85,-5.49,;8.37,-6.95,;9.4,-8.1,;10.91,-7.78,;11.39,-6.31,;10.36,-5.17,;11.94,-8.92,;13.45,-8.6,;13.92,-7.14,;14.48,-9.75,;15.62,-8.72,;13.33,-10.78,;13.49,-12.31,;12.09,-12.94,;11.06,-11.79,;11.83,-10.46,;15.51,-10.89,;17.04,-10.73,;17.67,-12.14,;16.52,-13.17,;15.19,-12.4,)|
Show InChI InChI=1S/C38H48N6O7S/c1-43(26-10-12-27(13-11-26)51-37(48)38(49,25-6-2-3-7-25)33-8-4-19-52-33)17-5-18-44-30-15-9-24(20-29(30)41-42-44)21-39-22-32(46)28-14-16-31(45)35-36(28)50-23-34(47)40-35/h4,8-9,14-16,19-20,25-27,32,39,45-46,49H,2-3,5-7,10-13,17-18,21-23H2,1H3,(H,40,47)/t26-,27-,32-,38+/m0/s1
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 1.40n/an/an/an/an/an/a



Almirall, S.A.

US Patent




US Patent US9757383 (2017)

More data for this
Ligand-Target Pair
Beta-2 adrenergic receptor and beta-3 adrenergic receptor


(Homo sapiens (Human))
BDBM200753
PNG
(US9233108, 18 | US9757383, Example 18)
Show SMILES CN(CCCn1nnc2cc(CNC[C@H](O)c3ccc(O)c4NC(=O)COc34)ccc12)[C@H]1CC[C@@H](CC1)OC(=O)[C@@](O)(C1CCCC1)c1cccs1 |wU:40.45,34.41,wD:40.44,14.14,31.34,(6.31,-4.67,;7.82,-4.35,;8.3,-2.88,;7.26,-1.74,;7.74,-.27,;6.71,.87,;5.18,.71,;4.55,2.12,;5.7,3.15,;5.7,4.69,;7.03,5.46,;7.03,7,;5.7,7.77,;5.7,9.31,;4.36,10.08,;3.03,9.31,;4.36,11.62,;5.7,12.39,;5.7,13.93,;4.36,14.7,;4.36,16.24,;3.03,13.93,;1.7,14.7,;.36,13.93,;-.97,14.7,;.36,12.39,;1.7,11.62,;3.03,12.39,;8.36,4.69,;8.36,3.15,;7.03,2.38,;8.85,-5.49,;8.37,-6.95,;9.4,-8.1,;10.91,-7.78,;11.39,-6.31,;10.36,-5.17,;11.94,-8.92,;13.45,-8.6,;13.92,-7.14,;14.48,-9.75,;15.62,-8.72,;13.33,-10.78,;13.49,-12.31,;12.09,-12.94,;11.06,-11.79,;11.83,-10.46,;15.51,-10.89,;17.04,-10.73,;17.67,-12.14,;16.52,-13.17,;15.19,-12.4,)|
Show InChI InChI=1S/C38H48N6O7S/c1-43(26-10-12-27(13-11-26)51-37(48)38(49,25-6-2-3-7-25)33-8-4-19-52-33)17-5-18-44-30-15-9-24(20-29(30)41-42-44)21-39-22-32(46)28-14-16-31(45)35-36(28)50-23-34(47)40-35/h4,8-9,14-16,19-20,25-27,32,39,45-46,49H,2-3,5-7,10-13,17-18,21-23H2,1H3,(H,40,47)/t26-,27-,32-,38+/m0/s1
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 1.40n/an/an/an/an/a25



ALMIRALL, S.A.

US Patent


Assay Description
The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are ov...


US Patent US9233108 (2016)


BindingDB Entry DOI: 10.7270/Q23J3BSN
More data for this
Ligand-Target Pair
Beta-2 adrenergic receptor and beta-3 adrenergic receptor


(Homo sapiens (Human))
BDBM200750
PNG
(US9233108, 15 | US9757383, Example 15)
Show SMILES CN(CCCn1c2ccc(CNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2oc1=O)[C@H]1CC[C@@H](CC1)OC(=O)C1(C)c2ccccc2Oc2ccccc12 |wU:35.42,wD:13.13,32.35,(3.58,2.63,;5.09,2.31,;5.57,.85,;4.54,-.3,;5.01,-1.76,;3.98,-2.91,;4.3,-4.41,;5.64,-5.18,;5.64,-6.72,;4.3,-7.49,;4.3,-9.03,;5.64,-9.8,;5.64,-11.34,;6.97,-12.11,;8.3,-11.34,;6.97,-13.65,;5.64,-14.42,;5.64,-15.96,;6.97,-16.73,;6.97,-18.27,;8.3,-15.96,;9.64,-16.73,;10.97,-15.96,;12.3,-16.73,;10.97,-14.42,;9.64,-13.65,;8.3,-14.42,;2.97,-6.72,;2.97,-5.18,;1.82,-4.15,;2.45,-2.75,;1.68,-1.41,;6.12,3.45,;7.63,3.13,;8.66,4.28,;8.18,5.74,;6.68,6.06,;5.65,4.92,;9.21,6.89,;8.74,8.35,;7.23,8.67,;9.77,9.5,;8.24,9.71,;10.03,11.01,;8.85,12,;9.12,13.52,;10.57,14.05,;11.75,13.06,;11.48,11.54,;12.66,10.55,;12.39,9.03,;13.57,8.04,;13.31,6.53,;11.86,6,;10.68,6.99,;10.95,8.51,)|
Show InChI InChI=1S/C44H46N4O8/c1-44(32-8-3-5-10-37(32)55-38-11-6-4-9-33(38)44)42(52)54-29-15-13-28(14-16-29)47(2)22-7-23-48-34-19-12-27(24-39(34)56-43(48)53)25-45-26-36(50)30-17-20-35(49)41-31(30)18-21-40(51)46-41/h3-6,8-12,17-21,24,28-29,36,45,49-50H,7,13-16,22-23,25-26H2,1-2H3,(H,46,51)/t28-,29-,36-/m0/s1
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 1.5n/an/an/an/an/an/a



Almirall, S.A.

US Patent




US Patent US9757383 (2017)

More data for this
Ligand-Target Pair
Beta-2 adrenergic receptor and beta-3 adrenergic receptor


(Homo sapiens (Human))
BDBM200750
PNG
(US9233108, 15 | US9757383, Example 15)
Show SMILES CN(CCCn1c2ccc(CNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2oc1=O)[C@H]1CC[C@@H](CC1)OC(=O)C1(C)c2ccccc2Oc2ccccc12 |wU:35.42,wD:13.13,32.35,(3.58,2.63,;5.09,2.31,;5.57,.85,;4.54,-.3,;5.01,-1.76,;3.98,-2.91,;4.3,-4.41,;5.64,-5.18,;5.64,-6.72,;4.3,-7.49,;4.3,-9.03,;5.64,-9.8,;5.64,-11.34,;6.97,-12.11,;8.3,-11.34,;6.97,-13.65,;5.64,-14.42,;5.64,-15.96,;6.97,-16.73,;6.97,-18.27,;8.3,-15.96,;9.64,-16.73,;10.97,-15.96,;12.3,-16.73,;10.97,-14.42,;9.64,-13.65,;8.3,-14.42,;2.97,-6.72,;2.97,-5.18,;1.82,-4.15,;2.45,-2.75,;1.68,-1.41,;6.12,3.45,;7.63,3.13,;8.66,4.28,;8.18,5.74,;6.68,6.06,;5.65,4.92,;9.21,6.89,;8.74,8.35,;7.23,8.67,;9.77,9.5,;8.24,9.71,;10.03,11.01,;8.85,12,;9.12,13.52,;10.57,14.05,;11.75,13.06,;11.48,11.54,;12.66,10.55,;12.39,9.03,;13.57,8.04,;13.31,6.53,;11.86,6,;10.68,6.99,;10.95,8.51,)|
Show InChI InChI=1S/C44H46N4O8/c1-44(32-8-3-5-10-37(32)55-38-11-6-4-9-33(38)44)42(52)54-29-15-13-28(14-16-29)47(2)22-7-23-48-34-19-12-27(24-39(34)56-43(48)53)25-45-26-36(50)30-17-20-35(49)41-31(30)18-21-40(51)46-41/h3-6,8-12,17-21,24,28-29,36,45,49-50H,7,13-16,22-23,25-26H2,1-2H3,(H,46,51)/t28-,29-,36-/m0/s1
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 1.5n/an/an/an/an/a25



ALMIRALL, S.A.

US Patent


Assay Description
The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are ov...


US Patent US9233108 (2016)


BindingDB Entry DOI: 10.7270/Q23J3BSN
More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM221906
PNG
(US9315463, 18)
Show SMILES CN(CCC(=O)Nc1cc(F)c(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1F)[C@H]1CC[C@@H](CC1)OC(=O)C(O)(c1cccs1)c1cccs1 |r,wU:15.15,35.41,wD:32.34,(4.61,5.39,;4.61,3.85,;3.27,3.08,;1.94,3.85,;.61,3.08,;.61,1.54,;-.73,3.85,;-2.06,3.08,;-2.06,1.54,;-3.39,.77,;-3.39,-.77,;-4.73,1.54,;-6.06,.77,;-7.39,1.54,;-8.73,.77,;-10.06,1.54,;-10.06,3.08,;-11.4,.77,;-12.73,1.54,;-14.06,.77,;-14.06,-.77,;-15.4,-1.54,;-12.73,-1.54,;-12.73,-3.08,;-11.4,-3.85,;-11.4,-5.39,;-10.06,-3.08,;-10.06,-1.54,;-11.4,-.77,;-4.73,3.08,;-3.39,3.85,;-3.39,5.39,;5.94,3.08,;5.94,1.54,;7.28,.77,;8.61,1.54,;8.61,3.08,;7.28,3.85,;9.94,.77,;11.28,1.54,;11.28,3.08,;12.61,.77,;13.94,,;13.38,2.1,;12.9,3.57,;14.15,4.47,;15.4,3.57,;14.92,2.1,;11.84,-.56,;10.38,-1.04,;10.38,-2.58,;11.84,-3.06,;12.75,-1.81,)|
Show InChI InChI=1/C38H40F2N4O7S2/c1-44(23-6-8-24(9-7-23)51-37(49)38(50,32-4-2-16-52-32)33-5-3-17-53-33)15-14-35(48)42-29-19-27(39)22(18-28(29)40)20-41-21-31(46)25-10-12-30(45)36-26(25)11-13-34(47)43-36/h2-5,10-13,16-19,23-24,31,41,45-46,50H,6-9,14-15,20-21H2,1H3,(H,42,48)(H,43,47)/t23-,24-,31-/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 1.60n/an/an/an/an/an/a



Almirall, S.A.

US Patent


Assay Description
The study of binding to human muscarinic M1, M2, M3, M4 and M5 receptors was performed using commercial membranes (Perkin Elmer) prepared from CHO-K1...


US Patent US9315463 (2016)


BindingDB Entry DOI: 10.7270/Q24X56MM
More data for this
Ligand-Target Pair
Beta-2 adrenergic receptor and beta-3 adrenergic receptor


(Homo sapiens (Human))
BDBM221902
PNG
(US9315463, 12)
Show SMILES COc1cc(NC(=O)OCCN(C)[C@H]2CC[C@@H](CC2)OC(=O)C(O)(c2cccs2)c2cccs2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12 |r,wU:41.45,13.12,wD:16.19,(-5.85,-3.32,;-4.52,-2.55,;-4.52,-1.01,;-3.19,-.24,;-3.19,1.3,;-1.85,2.07,;-.52,1.3,;-.52,-.24,;.82,2.07,;2.15,1.3,;3.48,2.07,;4.82,1.3,;4.82,-.24,;6.15,2.07,;6.15,3.61,;7.48,4.38,;8.82,3.61,;8.82,2.07,;7.48,1.3,;10.15,4.38,;11.49,3.61,;11.49,2.07,;12.82,4.38,;12.05,5.72,;13.59,3.05,;15.13,3.05,;15.6,1.58,;14.36,.68,;13.11,1.58,;14.15,5.15,;14.15,6.69,;15.62,7.17,;16.52,5.92,;15.62,4.68,;-4.52,2.07,;-4.52,3.61,;-5.85,1.3,;-5.85,-.24,;-7.19,-1.01,;-8.52,-.24,;-9.85,-1.01,;-11.19,-.24,;-11.19,1.3,;-12.52,-1.01,;-13.85,-.24,;-15.19,-1.01,;-15.19,-2.55,;-16.52,-3.32,;-13.85,-3.32,;-13.85,-4.86,;-12.52,-5.63,;-12.52,-7.17,;-11.19,-4.86,;-11.19,-3.32,;-12.52,-2.55,)|
Show InChI InChI=1/C39H43ClN4O9S2/c1-44(24-7-9-25(10-8-24)53-37(48)39(50,33-5-3-17-54-33)34-6-4-18-55-34)15-16-52-38(49)42-29-20-32(51-2)23(19-28(29)40)21-41-22-31(46)26-11-13-30(45)36-27(26)12-14-35(47)43-36/h3-6,11-14,17-20,24-25,31,41,45-46,50H,7-10,15-16,21-22H2,1-2H3,(H,42,49)(H,43,47)/t24-,25-,31-/s2
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 1.60n/an/an/an/an/a25



Almirall, S.A.

US Patent


Assay Description
The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are ov...


US Patent US9315463 (2016)


BindingDB Entry DOI: 10.7270/Q24X56MM
More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM221902
PNG
(US9315463, 12)
Show SMILES COc1cc(NC(=O)OCCN(C)[C@H]2CC[C@@H](CC2)OC(=O)C(O)(c2cccs2)c2cccs2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12 |r,wU:41.45,13.12,wD:16.19,(-5.85,-3.32,;-4.52,-2.55,;-4.52,-1.01,;-3.19,-.24,;-3.19,1.3,;-1.85,2.07,;-.52,1.3,;-.52,-.24,;.82,2.07,;2.15,1.3,;3.48,2.07,;4.82,1.3,;4.82,-.24,;6.15,2.07,;6.15,3.61,;7.48,4.38,;8.82,3.61,;8.82,2.07,;7.48,1.3,;10.15,4.38,;11.49,3.61,;11.49,2.07,;12.82,4.38,;12.05,5.72,;13.59,3.05,;15.13,3.05,;15.6,1.58,;14.36,.68,;13.11,1.58,;14.15,5.15,;14.15,6.69,;15.62,7.17,;16.52,5.92,;15.62,4.68,;-4.52,2.07,;-4.52,3.61,;-5.85,1.3,;-5.85,-.24,;-7.19,-1.01,;-8.52,-.24,;-9.85,-1.01,;-11.19,-.24,;-11.19,1.3,;-12.52,-1.01,;-13.85,-.24,;-15.19,-1.01,;-15.19,-2.55,;-16.52,-3.32,;-13.85,-3.32,;-13.85,-4.86,;-12.52,-5.63,;-12.52,-7.17,;-11.19,-4.86,;-11.19,-3.32,;-12.52,-2.55,)|
Show InChI InChI=1/C39H43ClN4O9S2/c1-44(24-7-9-25(10-8-24)53-37(48)39(50,33-5-3-17-54-33)34-6-4-18-55-34)15-16-52-38(49)42-29-20-32(51-2)23(19-28(29)40)21-41-22-31(46)26-11-13-30(45)36-27(26)12-14-35(47)43-36/h3-6,11-14,17-20,24-25,31,41,45-46,50H,7-10,15-16,21-22H2,1-2H3,(H,42,49)(H,43,47)/t24-,25-,31-/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 1.60n/an/an/an/an/an/a



Almirall, S.A.

US Patent


Assay Description
The study of binding to human muscarinic M1, M2, M3, M4 and M5 receptors was performed using commercial membranes (Perkin Elmer) prepared from CHO-K1...


US Patent US9315463 (2016)


BindingDB Entry DOI: 10.7270/Q24X56MM
More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM221910
PNG
(US9315463, 26)
Show SMILES COc1cc(NC(=O)OCCN(C)[C@H]2CC[C@@H](CC2)OC(=O)C(O)(c2cccs2)c2cccs2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2NC(=O)COc12 |r,wU:41.45,16.19,wD:13.12,(-2.73,-3.84,;-4.06,-3.07,;-4.06,-1.53,;-2.73,-.76,;-2.73,.78,;-1.39,1.55,;-.06,.78,;-.06,-.76,;1.27,1.55,;2.61,.78,;3.94,1.55,;5.28,.78,;5.28,-.76,;6.61,1.55,;7.94,.78,;9.28,1.55,;9.28,3.09,;7.94,3.86,;6.61,3.09,;10.61,3.86,;11.94,3.09,;11.94,1.55,;13.28,3.86,;14.61,4.63,;14.05,2.53,;13.57,1.06,;14.82,.16,;16.06,1.06,;15.59,2.53,;12.51,5.2,;13.41,6.44,;12.51,7.69,;11.04,7.21,;11.04,5.67,;-4.06,1.55,;-4.06,3.09,;-5.39,.78,;-5.39,-.76,;-6.73,-1.53,;-8.06,-.76,;-9.39,-1.53,;-10.73,-.76,;-10.73,.78,;-12.06,-1.53,;-13.4,-.76,;-14.73,-1.53,;-14.73,-3.07,;-16.06,-3.84,;-13.4,-3.84,;-13.4,-5.38,;-12.06,-6.15,;-12.06,-7.69,;-10.73,-5.38,;-10.73,-3.84,;-12.06,-3.07,)|
Show InChI InChI=1/C38H43ClN4O10S2/c1-43(23-7-9-24(10-8-23)53-36(47)38(49,31-5-3-15-54-31)32-6-4-16-55-32)13-14-51-37(48)41-27-18-30(50-2)22(17-26(27)39)19-40-20-29(45)25-11-12-28(44)34-35(25)52-21-33(46)42-34/h3-6,11-12,15-18,23-24,29,40,44-45,49H,7-10,13-14,19-21H2,1-2H3,(H,41,48)(H,42,46)/t23-,24-,29-/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 1.70n/an/an/an/an/an/a



Almirall, S.A.

US Patent


Assay Description
The study of binding to human muscarinic M1, M2, M3, M4 and M5 receptors was performed using commercial membranes (Perkin Elmer) prepared from CHO-K1...


US Patent US9315463 (2016)


BindingDB Entry DOI: 10.7270/Q24X56MM
More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM221905
PNG
(US9315463, 16)
Show SMILES COc1cc(NC(=O)CCN(C)[C@H]2CC[C@@H](CC2)OC(=O)C(O)(c2cccs2)c2cccs2)c(F)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12 |r,wU:40.44,15.18,wD:12.11,(-2.06,-1.54,;-3.39,-.77,;-3.39,.77,;-2.06,1.54,;-2.06,3.08,;-.73,3.85,;.61,3.08,;.61,1.54,;1.94,3.85,;3.27,3.08,;4.61,3.85,;4.61,5.39,;5.94,3.08,;5.94,1.54,;7.28,.77,;8.61,1.54,;8.61,3.08,;7.28,3.85,;9.94,.77,;11.28,1.54,;11.28,3.08,;12.61,.77,;13.94,,;13.38,2.1,;12.9,3.57,;14.15,4.47,;15.4,3.57,;14.92,2.1,;11.84,-.56,;10.38,-1.04,;10.38,-2.58,;11.84,-3.06,;12.75,-1.81,;-3.39,3.85,;-3.39,5.39,;-4.73,3.08,;-4.73,1.54,;-6.06,.77,;-7.39,1.54,;-8.73,.77,;-10.06,1.54,;-10.06,3.08,;-11.4,.77,;-12.73,1.54,;-14.06,.77,;-14.06,-.77,;-15.4,-1.54,;-12.73,-1.54,;-12.73,-3.08,;-11.4,-3.85,;-11.4,-5.39,;-10.06,-3.08,;-10.06,-1.54,;-11.4,-.77,)|
Show InChI InChI=1/C39H43FN4O8S2/c1-44(24-7-9-25(10-8-24)52-38(49)39(50,33-5-3-17-53-33)34-6-4-18-54-34)16-15-36(48)42-29-20-32(51-2)23(19-28(29)40)21-41-22-31(46)26-11-13-30(45)37-27(26)12-14-35(47)43-37/h3-6,11-14,17-20,24-25,31,41,45-46,50H,7-10,15-16,21-22H2,1-2H3,(H,42,48)(H,43,47)/t24-,25-,31-/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 2n/an/an/an/an/an/a



Almirall, S.A.

US Patent


Assay Description
The study of binding to human muscarinic M1, M2, M3, M4 and M5 receptors was performed using commercial membranes (Perkin Elmer) prepared from CHO-K1...


US Patent US9315463 (2016)


BindingDB Entry DOI: 10.7270/Q24X56MM
More data for this
Ligand-Target Pair
Beta-2 adrenergic receptor and beta-3 adrenergic receptor


(Homo sapiens (Human))
BDBM221904
PNG
(US9315463, 15)
Show SMILES COc1cc(NC(=O)CCCN[C@H]2CC[C@@H](CC2)OC(=O)C(O)(c2cccs2)c2cccs2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12 |r,wU:40.44,15.18,wD:12.11,(-5.39,-3.84,;-4.06,-3.07,;-4.06,-1.53,;-2.73,-.76,;-2.73,.78,;-1.39,1.55,;-.06,.78,;-.06,-.76,;1.27,1.55,;2.61,.78,;3.94,1.55,;5.28,.78,;6.61,1.55,;7.94,.78,;9.28,1.55,;9.28,3.09,;7.94,3.86,;6.61,3.09,;10.61,3.86,;11.94,3.09,;11.94,1.55,;13.28,3.86,;14.61,4.63,;14.05,2.53,;13.57,1.06,;14.82,.16,;16.06,1.06,;15.59,2.53,;12.51,5.2,;13.41,6.44,;12.51,7.69,;11.04,7.21,;11.04,5.67,;-4.06,1.55,;-4.06,3.09,;-5.39,.78,;-5.39,-.76,;-6.73,-1.53,;-8.06,-.76,;-9.39,-1.53,;-10.73,-.76,;-10.73,.78,;-12.06,-1.53,;-13.4,-.76,;-14.73,-1.53,;-14.73,-3.07,;-16.06,-3.84,;-13.4,-3.84,;-13.4,-5.38,;-12.06,-6.15,;-12.06,-7.69,;-10.73,-5.38,;-10.73,-3.84,;-12.06,-3.07,)|
Show InChI InChI=1/C39H43ClN4O8S2/c1-51-32-20-29(28(40)19-23(32)21-41-22-31(46)26-12-14-30(45)37-27(26)13-15-36(48)44-37)43-35(47)7-2-16-42-24-8-10-25(11-9-24)52-38(49)39(50,33-5-3-17-53-33)34-6-4-18-54-34/h3-6,12-15,17-20,24-25,31,41-42,45-46,50H,2,7-11,16,21-22H2,1H3,(H,43,47)(H,44,48)/t24-,25-,31-/s2
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 2.10n/an/an/an/an/a25



Almirall, S.A.

US Patent


Assay Description
The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are ov...


US Patent US9315463 (2016)


BindingDB Entry DOI: 10.7270/Q24X56MM
More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM221903
PNG
(US9315463, 13)
Show SMILES COc1cc(NC(=O)CCN(C)[C@H]2CC[C@@](C)(CC2)OC(=O)C(O)(c2cccs2)c2cccs2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12 |r,wU:41.45,15.19,wD:12.11,15.15,(-4.73,-1.54,;-3.39,-.77,;-3.39,.77,;-2.06,1.54,;-2.06,3.08,;-.73,3.85,;.61,3.08,;.61,1.54,;1.94,3.85,;3.27,3.08,;4.61,3.85,;4.61,5.39,;5.94,3.08,;5.94,1.54,;7.28,.77,;8.61,1.54,;9.94,2.31,;8.61,3.08,;7.28,3.85,;9.94,.77,;11.28,1.54,;11.28,3.08,;12.61,.77,;13.94,,;13.38,2.1,;12.9,3.57,;14.15,4.47,;15.4,3.57,;14.92,2.1,;11.84,-.56,;10.38,-1.04,;10.38,-2.58,;11.84,-3.06,;12.75,-1.81,;-3.39,3.85,;-3.39,5.39,;-4.73,3.08,;-4.73,1.54,;-6.06,.77,;-7.39,1.54,;-8.73,.77,;-10.06,1.54,;-10.06,3.08,;-11.4,.77,;-12.73,1.54,;-14.06,.77,;-14.06,-.77,;-15.4,-1.54,;-12.73,-1.54,;-12.73,-3.08,;-11.4,-3.85,;-11.4,-5.39,;-10.06,-3.08,;-10.06,-1.54,;-11.4,-.77,)|
Show InChI InChI=1/C40H45ClN4O8S2/c1-39(53-38(50)40(51,33-6-4-18-54-33)34-7-5-19-55-34)15-12-25(13-16-39)45(2)17-14-36(49)43-29-21-32(52-3)24(20-28(29)41)22-42-23-31(47)26-8-10-30(46)37-27(26)9-11-35(48)44-37/h4-11,18-21,25,31,42,46-47,51H,12-17,22-23H2,1-3H3,(H,43,49)(H,44,48)/t25-,31-,39-/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 2.10n/an/an/an/an/an/a



Almirall, S.A.

US Patent


Assay Description
The study of binding to human muscarinic M1, M2, M3, M4 and M5 receptors was performed using commercial membranes (Perkin Elmer) prepared from CHO-K1...


US Patent US9315463 (2016)


BindingDB Entry DOI: 10.7270/Q24X56MM
More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM221901
PNG
(US9315463, 10)
Show SMILES CN(CCC(=O)Nc1ccc(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1Cl)[C@H]1CC[C@@H](CC1)OC(=O)C(O)(c1cccs1)c1cccs1 |r,wU:14.14,34.40,wD:31.33,(4.15,5.39,;4.15,3.85,;2.82,3.08,;1.48,3.85,;.15,3.08,;.15,1.54,;-1.18,3.85,;-2.52,3.08,;-2.52,1.54,;-3.85,.77,;-5.19,1.54,;-6.52,.77,;-7.85,1.54,;-9.19,.77,;-10.52,1.54,;-10.52,3.08,;-11.85,.77,;-13.19,1.54,;-14.52,.77,;-14.52,-.77,;-15.86,-1.54,;-13.19,-1.54,;-13.19,-3.08,;-11.85,-3.85,;-11.85,-5.39,;-10.52,-3.08,;-10.52,-1.54,;-11.85,-.77,;-5.19,3.08,;-3.85,3.85,;-3.85,5.39,;5.48,3.08,;5.48,1.54,;6.82,.77,;8.15,1.54,;8.15,3.08,;6.82,3.85,;9.48,.77,;10.82,1.54,;10.82,3.08,;12.15,.77,;13.49,,;12.15,-.77,;13.4,-1.68,;12.92,-3.14,;11.38,-3.14,;10.91,-1.68,;13.49,1.54,;14.95,1.06,;15.86,2.31,;14.95,3.56,;13.49,3.08,)|
Show InChI InChI=1/C38H41ClN4O7S2/c1-43(24-7-9-25(10-8-24)50-37(48)38(49,32-4-2-18-51-32)33-5-3-19-52-33)17-16-35(47)41-29-13-6-23(20-28(29)39)21-40-22-31(45)26-11-14-30(44)36-27(26)12-15-34(46)42-36/h2-6,11-15,18-20,24-25,31,40,44-45,49H,7-10,16-17,21-22H2,1H3,(H,41,47)(H,42,46)/t24-,25-,31-/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 2.20n/an/an/an/an/an/a



Almirall, S.A.

US Patent


Assay Description
The study of binding to human muscarinic M1, M2, M3, M4 and M5 receptors was performed using commercial membranes (Perkin Elmer) prepared from CHO-K1...


US Patent US9315463 (2016)


BindingDB Entry DOI: 10.7270/Q24X56MM
More data for this
Ligand-Target Pair
Beta-2 adrenergic receptor and beta-3 adrenergic receptor


(Homo sapiens (Human))
BDBM221903
PNG
(US9315463, 13)
Show SMILES COc1cc(NC(=O)CCN(C)[C@H]2CC[C@@](C)(CC2)OC(=O)C(O)(c2cccs2)c2cccs2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12 |r,wU:41.45,15.19,wD:12.11,15.15,(-4.73,-1.54,;-3.39,-.77,;-3.39,.77,;-2.06,1.54,;-2.06,3.08,;-.73,3.85,;.61,3.08,;.61,1.54,;1.94,3.85,;3.27,3.08,;4.61,3.85,;4.61,5.39,;5.94,3.08,;5.94,1.54,;7.28,.77,;8.61,1.54,;9.94,2.31,;8.61,3.08,;7.28,3.85,;9.94,.77,;11.28,1.54,;11.28,3.08,;12.61,.77,;13.94,,;13.38,2.1,;12.9,3.57,;14.15,4.47,;15.4,3.57,;14.92,2.1,;11.84,-.56,;10.38,-1.04,;10.38,-2.58,;11.84,-3.06,;12.75,-1.81,;-3.39,3.85,;-3.39,5.39,;-4.73,3.08,;-4.73,1.54,;-6.06,.77,;-7.39,1.54,;-8.73,.77,;-10.06,1.54,;-10.06,3.08,;-11.4,.77,;-12.73,1.54,;-14.06,.77,;-14.06,-.77,;-15.4,-1.54,;-12.73,-1.54,;-12.73,-3.08,;-11.4,-3.85,;-11.4,-5.39,;-10.06,-3.08,;-10.06,-1.54,;-11.4,-.77,)|
Show InChI InChI=1/C40H45ClN4O8S2/c1-39(53-38(50)40(51,33-6-4-18-54-33)34-7-5-19-55-34)15-12-25(13-16-39)45(2)17-14-36(49)43-29-21-32(52-3)24(20-28(29)41)22-42-23-31(47)26-8-10-30(46)37-27(26)9-11-35(48)44-37/h4-11,18-21,25,31,42,46-47,51H,12-17,22-23H2,1-3H3,(H,43,49)(H,44,48)/t25-,31-,39-/s2
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 2.20n/an/an/an/an/a25



Almirall, S.A.

US Patent


Assay Description
The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are ov...


US Patent US9315463 (2016)


BindingDB Entry DOI: 10.7270/Q24X56MM
More data for this
Ligand-Target Pair
Beta-2 adrenergic receptor and beta-3 adrenergic receptor


(Homo sapiens (Human))
BDBM200747
PNG
(US9233108, 9 | US9757383, Example 9)
Show SMILES COc1cc(-c2noc(CCCN(C)[C@H]3CC[C@@H](CC3)OC(=O)C(O)(c3cccs3)c3cccs3)n2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12 |wU:17.20,wD:43.48,14.13,(3.51,-4.33,;4.85,-5.1,;6.18,-4.33,;6.18,-2.79,;7.51,-2.02,;7.51,-.48,;8.76,.43,;8.28,1.89,;6.74,1.89,;5.84,3.14,;6.46,4.54,;5.56,5.79,;6.18,7.2,;7.72,7.36,;5.28,8.44,;5.91,9.85,;5,11.09,;3.47,10.93,;2.84,9.53,;3.75,8.28,;2.56,12.18,;1.03,12.02,;.41,10.61,;.13,13.26,;1.37,14.17,;-.78,14.51,;-2.32,14.51,;-2.79,15.98,;-1.55,16.88,;-.3,15.98,;-1.12,12.36,;-1.12,10.82,;-2.58,10.34,;-3.49,11.59,;-2.58,12.84,;6.27,.43,;8.85,-2.79,;10.18,-2.02,;8.85,-4.33,;7.51,-5.1,;7.51,-6.64,;8.85,-7.41,;8.85,-8.95,;10.18,-9.72,;11.51,-8.95,;10.18,-11.26,;8.85,-12.03,;8.85,-13.57,;10.18,-14.34,;10.18,-15.88,;11.51,-13.57,;12.85,-14.34,;14.18,-13.57,;15.51,-14.34,;14.18,-12.03,;12.85,-11.26,;11.51,-12.03,)|
Show InChI InChI=1S/C41H44ClN5O8S2/c1-47(25-9-11-26(12-10-25)54-40(51)41(52,34-6-4-18-56-34)35-7-5-19-57-35)17-3-8-37-45-39(46-55-37)29-21-33(53-2)24(20-30(29)42)22-43-23-32(49)27-13-15-31(48)38-28(27)14-16-36(50)44-38/h4-7,13-16,18-21,25-26,32,43,48-49,52H,3,8-12,17,22-23H2,1-2H3,(H,44,50)/t25-,26-,32-/m0/s1
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 2.20n/an/an/an/an/a25



ALMIRALL, S.A.

US Patent


Assay Description
The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are ov...


US Patent US9233108 (2016)


BindingDB Entry DOI: 10.7270/Q23J3BSN
More data for this
Ligand-Target Pair
Beta-2 adrenergic receptor and beta-3 adrenergic receptor


(Homo sapiens (Human))
BDBM200747
PNG
(US9233108, 9 | US9757383, Example 9)
Show SMILES COc1cc(-c2noc(CCCN(C)[C@H]3CC[C@@H](CC3)OC(=O)C(O)(c3cccs3)c3cccs3)n2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12 |wU:17.20,wD:43.48,14.13,(3.51,-4.33,;4.85,-5.1,;6.18,-4.33,;6.18,-2.79,;7.51,-2.02,;7.51,-.48,;8.76,.43,;8.28,1.89,;6.74,1.89,;5.84,3.14,;6.46,4.54,;5.56,5.79,;6.18,7.2,;7.72,7.36,;5.28,8.44,;5.91,9.85,;5,11.09,;3.47,10.93,;2.84,9.53,;3.75,8.28,;2.56,12.18,;1.03,12.02,;.41,10.61,;.13,13.26,;1.37,14.17,;-.78,14.51,;-2.32,14.51,;-2.79,15.98,;-1.55,16.88,;-.3,15.98,;-1.12,12.36,;-1.12,10.82,;-2.58,10.34,;-3.49,11.59,;-2.58,12.84,;6.27,.43,;8.85,-2.79,;10.18,-2.02,;8.85,-4.33,;7.51,-5.1,;7.51,-6.64,;8.85,-7.41,;8.85,-8.95,;10.18,-9.72,;11.51,-8.95,;10.18,-11.26,;8.85,-12.03,;8.85,-13.57,;10.18,-14.34,;10.18,-15.88,;11.51,-13.57,;12.85,-14.34,;14.18,-13.57,;15.51,-14.34,;14.18,-12.03,;12.85,-11.26,;11.51,-12.03,)|
Show InChI InChI=1S/C41H44ClN5O8S2/c1-47(25-9-11-26(12-10-25)54-40(51)41(52,34-6-4-18-56-34)35-7-5-19-57-35)17-3-8-37-45-39(46-55-37)29-21-33(53-2)24(20-30(29)42)22-43-23-32(49)27-13-15-31(48)38-28(27)14-16-36(50)44-38/h4-7,13-16,18-21,25-26,32,43,48-49,52H,3,8-12,17,22-23H2,1-2H3,(H,44,50)/t25-,26-,32-/m0/s1
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 2.20n/an/an/an/an/an/a



Almirall, S.A.

US Patent




US Patent US9757383 (2017)

More data for this
Ligand-Target Pair
Displayed 1 to 50 (of 158 total )  |  Next  |  Last  >>
Jump to: